



## California Proposition 65 Certificate of Compliance

Adam Tech fully supports and hereby certifies all supplied parts and raw materials used in our production are in complete conformance to the latest requirements of the California Proposition 65 that was originally a new law entered into force on November 1986. Adam Tech's parts and raw materials used in our production do not contain any of the Prop 65 substances.

Adam Tech is committed to providing safe products consistent with the improvement and protection of human health and the environment through the better and earlier identification of the intrinsic properties of chemical substances.

STATE OF CALIFORNIA  
ENVIRONMENTAL PROTECTION AGENCY  
OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT  
SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986

CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY  
Updated 12/29/2023 Reviewed 12/29/2023

The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and republish In the Listing Mechanism column, "AB" denotes authoritative bodies, "SQE" denotes State's Qualified

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day) <sup>a</sup>
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	cancer	AB	26148-68-5	1-Jan-90	<a href="#">2</a>
Abiraterone acetate	developmental, female, male	<a href="#">FR</a>	154229-18-2	8-Apr-16	
Acetaldehyde	cancer	SQE	75-07-0	1-Apr-88	90 (inhalation)
Acetamide	cancer	AB	60-35-5	1-Jan-90	<a href="#">10</a>
Acetazolamide	developmental	<a href="#">FR</a>	59-66-5	20-Aug-99	
Acetochlor	cancer	SQE	34256-82-1	1-Jan-89	
Acetohydroxamic acid	developmental	FR	546-88-3	1-Apr-90	
2-Acetylaminofluorene	cancer	SQE	53-96-3	1-Jul-87	<a href="#">0.2</a>
Acifluorfen sodium	cancer	AB	62476-59-9	1-Jan-90	
Acrylamide	cancer	AB	79-06-1	1-Jan-90	0.2
Acrylamide	developmental, male	<a href="#">AB</a>	79-06-1	25-Feb-11	<a href="#">140</a>
Acrylonitrile	cancer	FR	107-13-1	1-Jul-87	0.7
Actinomycin D [ <a href="#">Basis for listing changed effective February 22, 2013</a> ]	cancer	<a href="#">FR</a>	50-76-0	1-Oct-89	<a href="#">0.00008</a>
Actinomycin D	developmental	FR	50-76-0	1-Oct-92	

AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide	cancer	SQE	3688-53-7	1-Jul-87	<a href="#">3</a>
Aflatoxins	cancer	SQE	---	1-Jan-88	
Alachlor	cancer	SQE	15972-60-8	1-Jan-89	
Alcoholic beverages	cancer	LC	---	29-Apr-11	
Alcoholic beverages, when associated with alcohol abuse	cancer	SQE	---	1-Jul-88	
Aldrin	cancer	SQE	309-00-2	1-Jul-88	0.04
All-trans retinoic acid	developmental	SQE	302-79-4	1-Jan-89	
<a href="#">Allyl chloride Delisted October 29, 1999 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">AB</a>	<a href="#">107-05-1</a>	<a href="#">1-Jan-90</a>	
Aloe vera, non-decolorized whole leaf extract	cancer	<a href="#">LC</a>	---	4-Dec-15	
Alprazolam	developmental	FR	28981-97-7	1-Jul-90	
Altretamine	developmental, male	<a href="#">FR</a>	645-05-6	20-Aug-99	
Amantadine hydrochloride	developmental	<a href="#">FR</a>	665-66-7	27-Feb-01	
Amikacin sulfate	developmental	FR	39831-55-5	1-Jul-90	
2-Aminoanthraquinone	cancer	LC	117-79-3	1-Oct-89	<a href="#">20</a>
p-Aminoazobenzene	cancer	AB	60-09-3	1-Jan-90	
o-Aminoazotoluene	cancer	SQE	97-56-3	1-Jul-87	<a href="#">0.2</a>
4-Aminobiphenyl (4-aminodiphenyl)	cancer	LC	92-67-1	27-Feb-87	<a href="#">0.03</a>
2-Amino-4-chlorophenol	cancer	<a href="#">LC</a>	95-85-2	13-Sep-19	
1-Amino-2,4-dibromoanthraquinone	cancer	<a href="#">AB</a>	81-49-2	26-Aug-97	
3-Amino-9-ethylcarbazole hydrochloride	cancer	SQE	6109-97-3	1-Jul-89	<a href="#">9</a>
2-Aminofluorene	cancer	<a href="#">SQE</a>	153-78-6	29-Jan-99	
Aminoglutethimide	developmental	FR	125-84-8	1-Jul-90	
Aminoglycosides	developmental	FR	---	1-Oct-92	
1-Amino-2-methylantraquinone	cancer	LC	82-28-0	1-Oct-89	<a href="#">5</a>
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	cancer	SQE	712-68-5	1-Jul-87	<a href="#">0.04</a>
4-Amino-2-nitrophenol	cancer	<a href="#">SQE</a>	119-34-6	29-Jan-99	
Aminopterin	developmental, female	SQE	54-62-6	1-Jul-87	
Amiodarone hydrochloride	developmental, female, male	<a href="#">FR</a>	19774-82-4	26-Aug-97	
Amitraz	developmental	<a href="#">AB</a>	33089-61-1	30-Mar-99	
Amitrole	cancer	SQE	61-82-5	1-Jul-87	<a href="#">0.7</a>
Amoxapine	developmental	<a href="#">FR</a>	14028-44-5	15-May-98	
Amsacrine	cancer	<a href="#">LC</a>	51264-14-3	7-Aug-09	

<a href="#">tert-Amyl methyl ether Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	<a href="#">LC</a>	<a href="#">994-05-8</a>	<a href="#">18-Dec-09</a>	
Anabolic steroids	female, male	FR	---	1-Apr-90	
Analgesic mixtures containing Phenacetin	cancer	LC	---	27-Feb-87	
Androstenedione	cancer	<a href="#">AB</a>	63-05-8	3-May-11	
Angiotensin converting enzyme (ACE) inhibitors	developmental	FR	---	1-Oct-92	
Aniline	cancer	AB	62-53-3	1-Jan-90	100
Aniline hydrochloride	cancer	<a href="#">AB</a>	142-04-1	15-May-98	
<i>o</i> -Anisidine	cancer	SQE	90-04-0	1-Jul-87	<a href="#">5</a>
<i>o</i> -Anisidine hydrochloride	cancer	SQE	134-29-2	1-Jul-87	<a href="#">7</a>
Anisindione	developmental	FR	117-37-3	1-Oct-92	
Anthracene	cancer	<a href="#">LC</a>	120-12-7	11-Aug-23	
Anthraquinone	cancer	<a href="#">AB</a>	84-65-1	28-Sep-07	
Antimony oxide (Antimony trioxide)	cancer	AB	1309-64-4	1-Oct-90	
Aramite	cancer	SQE	140-57-8	1-Jul-87	<a href="#">20</a>
Areca nut	cancer	<a href="#">LC</a>	---	3-Feb-06	
Aristolochic acids	cancer	<a href="#">LC</a>	---	9-Jul-04	
Arsenic (inorganic arsenic compounds)	cancer	LC	--	27-Feb-87	0.06 (inhalation) 10 (except inhalation)
Arsenic (inorganic oxides)	developmental	<a href="#">SQE</a>	---	1-May-97	
Asbestos	cancer	LC	1332-21-4	27-Feb-87	100 fibers/day (inhalation)
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	developmental, female	SQE	50-78-2	1-Jul-90	
Atenolol	developmental	<a href="#">FR</a>	29122-68-7	26-Aug-97	
Atrazine	developmental, female	<a href="#">AB</a>	1912-24-9	15-Jul-16	<a href="#">100 (oral)</a>
Auramine	cancer	SQE	492-80-8	1-Jul-87	<a href="#">0.8</a>
Auranofin	developmental	<a href="#">FR</a>	34031-32-8	29-Jan-99	
Avermectin B1 (Abamectin)	developmental	<a href="#">AB</a>	71751-41-2	3-Dec-10	<a href="#">4.4</a>
Azacitidine	cancer	AB	320-67-2	1-Jan-92	
Azaserine	cancer	SQE	115-02-6	1-Jul-87	<a href="#">0.06</a>
Azathioprine	cancer	LC	446-86-6	27-Feb-87	<a href="#">0.4</a>
Azathioprine	developmental	FR	446-86-6	1-Sep-96	
Azobenzene	cancer	AB	103-33-3	1-Jan-90	6

Barbiturates	developmental	FR	---	1-Oct-92	
Beclomethasone dipropionate	developmental	<a href="#">FR</a>	9/8/5534	15-May-98	
Benomyl	developmental, male	SQE	17804-35-2	1-Jul-91	
Benthiavalicarb-isopropyl	cancer	<a href="#">AB</a>	177406-68-7	1-Jul-08	
Benz[a]anthracene	cancer	SQE	56-55-3	1-Jul-87	<a href="#">0.033 (oral)</a>
Benzene	cancer	LC	71-43-2	27-Feb-87	<a href="#">6.4 (oral)</a>
					<a href="#">13 (inhalation)</a>
					<a href="#">24 (oral)</a>
Benzene	developmental, male	<a href="#">SQE</a>	71-43-2	26-Dec-97	<a href="#">49 (inhalation)</a>
Benzidine [and its salts]	cancer	LC	92-87-5	27-Feb-87	0.001
Benzidine-based dyes	cancer	FR	---	1-Oct-92	
Benzodiazepines	developmental	FR	---	1-Oct-92	
Benzo[b]fluoranthene	cancer	SQE	205-99-2	1-Jul-87	<a href="#">0.096 (oral)</a>
Benzo[j]fluoranthene	cancer	SQE	205-82-3	1-Jul-87	<a href="#">0.11 (oral)</a>
Benzo[k]fluoranthene	cancer	SQE	207-08-9	1-Jul-87	
Benzofuran	cancer	AB	271-89-6	1-Oct-90	<a href="#">1.1</a>
Benzophenone	cancer	<a href="#">LC</a>	119-61-9	22-Jun-12	
Benzo[a]pyrene	cancer	SQE	50-32-8	1-Jul-87	0.06
Benzotrichloride	cancer	SQE	98-07-7	1-Jul-87	
Benzphetamine hydrochloride	developmental	FR	5411-22-3	1-Apr-90	
Benzyl chloride	cancer	AB	100-44-7	1-Jan-90	4
Benzyl violet 4B	cancer	SQE	1694-09-3	1-Jul-87	<a href="#">30</a>
Beryllium and beryllium compounds	cancer	SQE	---	1-Oct-87	
Beryllium					0.1
Beryllium oxide					0.1
Beryllium sulfate					0.0002
Betel quid with tobacco	cancer	AB	---	1-Jan-90	
Betel quid without tobacco	cancer	<a href="#">LC</a>	---	3-Feb-06	
Bevacizumab	developmental, female	<a href="#">FR</a>	216974-75-3	8-Mar-19	
2,2-Bis(bromomethyl)-1,3-propanediol	cancer	AB	3296-90-0	1-May-96	
Bis(2-chloroethyl)ether	cancer	SQE	111-44-4	1-Apr-88	0.3
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	cancer	LC	494-03-1	27-Feb-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	cancer	SQE	154-93-8	1-Jul-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	FR	154-93-8	1-Jul-90	
Bis(chloromethyl)ether	cancer	LC	542-88-1	27-Feb-87	0.02
Bis(2-chloro-1-methylethyl)ether, technical grade	cancer	<a href="#">SQE</a>	---	29-Oct-99	
Bisphenol A (BPA)	female	<a href="#">SQE</a>	80-05-7	11-May-15	<a href="#">3 (dermal exposure from solid materials)</a>
Bisphenol A (BPA)	developmental	AB	80-05-7	18-Dec-20	

Bisphenol S (BPS)	female	<a href="#">SQE</a>	80-09-1	29-Dec-23	
Bitumens, extracts of steam-refined and air refined	cancer	AB	---	1-Jan-90	
Bracken fern	cancer	AB	---	1-Jan-90	
Bromacil lithium salt	developmental	<a href="#">AB</a>	53404-19-6	18-May-99	
Bromacil lithium salt	male	<a href="#">SQE</a>	53404-19-6	17-Jan-03	
Bromate	cancer	<a href="#">AB</a>	15541-45-4	31-May-02	
Bromochloroacetic acid	cancer	<a href="#">AB</a>	5589-96-8	6-Apr-10	<a href="#">0.7</a>
1-Bromo-3-chloropropane	cancer	<a href="#">LC</a>	109-70-6	27-Jan-23	
Bromodichloroacetic acid	cancer	<a href="#">AB</a>	71133-14-7	29-Jul-16	<a href="#">0.95</a>
Bromodichloromethane	cancer	AB	75-27-4	1-Jan-90	5
Bromoethane	cancer	<a href="#">AB</a>	74-96-4	22-Dec-00	<a href="#">96</a>
Bromoform	cancer	AB	75-25-2	1-Apr-91	<a href="#">64</a>
1-Bromopropane (1-BP)	cancer	<a href="#">AB</a>	106-94-5	5-Aug-16	
1-Bromopropane (1-BP)	developmental, female, male	<a href="#">AB</a>	106-94-5	7-Dec-04	
2-Bromopropane (2-BP)	cancer	<a href="#">LC</a>	75-26-3	11-Aug-23	
2-Bromopropane (2-BP)	female, male	<a href="#">AB</a>	75-26-3	31-May-05	
Bromoxynil	developmental	FR	1689-84-5	1-Oct-90	
Bromoxynil octanoate	developmental	<a href="#">AB</a>	1689-99-2	18-May-99	
Butabarbital sodium	developmental	FR	143-81-7	1-Oct-92	
1,3-Butadiene	cancer	SQE	106-99-0	1-Apr-88	0.4
1,3-Butadiene	developmental, female, male	<a href="#">AB</a>	106-99-0	16-Apr-04	
1,4-Butanediol dimethanesulfonate (Busulfan)	cancer	LC	55-98-1	27-Feb-87	
1,4-Butanediol dimethanesulfonate (Busulfan)	developmental	SQE	55-98-1	1-Jan-89	
Butylated hydroxyanisole	cancer	AB	25013-16-5	1-Jan-90	4000
Butyl benzyl phthalate (BBP) <sup>d</sup>	developmental	<a href="#">AB</a>	85-68-7	2-Dec-05	<a href="#">1200 (oral)</a>
1-Butyl glycidyl ether	cancer	<a href="#">LC</a>	8/6/2426	27-Jan-23	
<a href="#">n-Butyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]</a>	<del>male</del>	<a href="#">LC</a>	<a href="#">8/6/2426</a>	<a href="#">7-Aug-09</a>	
beta-Butyrolactone	cancer	SQE	3068-88-0	1-Jul-87	<a href="#">0.7</a>
Cacodylic acid	cancer	AB	75-60-5	1-May-96	
Cadmium	developmental, male	<a href="#">SQE</a>	---	1-May-97	<a href="#">4.1 (oral)</a>
Cadmium and cadmium compounds	cancer	SQE	---	1-Oct-87	
Cadmium					0.05 (inhalation)
Cannabis (marijuana) smoke	developmental	<a href="#">SQE</a>	---	3-Jan-20	
Caffeic acid	cancer	AB	331-39-5	1-Oct-94	
Captafol	cancer	<a href="#">SQE</a>	6/1/2425	1-Oct-88	<a href="#">5</a>
Captan	cancer	AB	133-06-2	1-Jan-90	<a href="#">300</a>

Carbamazepine	developmental	<a href="#">FR</a>	298-46-4	29-Jan-99	
Carbaryl	cancer	<a href="#">AB</a>	63-25-2	5-Feb-10	
Carbaryl [ <a href="#">Basis for listing changed effective December 27, 2013</a> ]	developmental, female, male	<a href="#">AB</a>	63-25-2	7-Aug-09	
Carbazole	cancer	AB	86-74-8	1-May-96	<a href="#">4.1</a>
Carbon black (airborne, unbound particles of respirable size)	cancer	<a href="#">AB</a>	1333-86-4	21-Feb-03	
Carbon-black extracts	cancer	AB	---	1-Jan-90	
Carbon disulfide	developmental, female, male	SQE	75-15-0	1-Jul-89	
Carbon monoxide	developmental	SQE	630-08-0	1-Jul-89	
Carbon tetrachloride	cancer	SQE	56-23-5	1-Oct-87	5
Carboplatin	developmental	FR	41575-94-4	1-Jul-90	
N-Carboxymethyl-N-nitrosourea	cancer	<a href="#">SQE</a>	60391-92-6	25-Jan-02	<a href="#">0.7</a>
Catechol	cancer	<a href="#">AB</a>	120-80-9	15-Jul-03	
Ceramic fibers (airborne particles of respirable size)	cancer	AB	---	1-Jul-90	
Certain combined chemotherapy for lymphomas	cancer	LC	---	27-Feb-87	
Chenodiol	developmental	FR	474-25-9	1-Apr-90	
Chloral	cancer	<a href="#">LC</a>	75-87-6	13-Sep-13	
Chloral hydrate	cancer	<a href="#">LC</a>	302-17-0	13-Sep-13	
Chlorambucil	cancer	LC	305-03-3	27-Feb-87	<a href="#">0.002</a>
Chlorambucil	developmental	SQE	305-03-3	1-Jan-89	
<a href="#">Chloramphenicol Delisted January 4, 2013 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">LC</a>	<a href="#">56-75-7</a>	<a href="#">1-Oct-89</a>	
Chloramphenicol sodium succinate	cancer	<a href="#">FR</a>	982-57-0	27-Sep-13	
Chlorcyclizine hydrochloride	developmental	FR	1620-21-9	1-Jul-87	
Chlordane	cancer	SQE	57-74-9	1-Jul-88	0.5
Chlordecone (Kepone)	cancer	SQE	143-50-0	1-Jan-88	<a href="#">0.04</a>
Chlordecone (Kepone)	developmental	SQE	143-50-0	1-Jan-89	
Chlordiazepoxide	developmental	FR	58-25-3	1-Jan-92	
Chlordiazepoxide hydrochloride	developmental	FR	438-41-5	1-Jan-92	
Chlordimeform	cancer	SQE	6164-98-3	1-Jan-89	
Chlorendic acid	cancer	SQE	115-28-6	1-Jul-89	<a href="#">8</a>
Chlorinated paraffins (Average chain length, C12;approximately 60 percent chlorine by weight)	cancer	SQE	108171-26-2	1-Jul-89	<a href="#">8</a>
p-Chloroaniline	cancer	AB	106-47-8	1-Oct-94	<a href="#">1.5</a>
p-Chloroaniline hydrochloride	cancer	<a href="#">AB</a>	20265-96-7	15-May-98	<a href="#">1.9</a>

<a href="#">Chlorodibromomethane Delisted October 29, 1999 [Click here for the basis for delisting]</a>	cancer	AB	<del>124-48-1</del>	1-Jan-90	
Chloroethane (Ethyl chloride)	cancer	AB	75-00-3	1-Jul-90	<a href="#">150</a>
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	cancer	SQE	13010-47-4	1-Jan-88	
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	developmental	FR	13010-47-4	1-Jul-90	
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)	cancer	SQE	13909-09-6	1-Oct-88	
Chloroform	cancer	SQE	67-66-3	1-Oct-87	20 (oral) 40 (inhalation)
Chloroform <a href="#">[Basis for listing changed effective December 23, 2016]</a>	developmental	<a href="#">SQE</a>	67-66-3	7-Aug-09	
Chloromethyl methyl ether (technical grade)	cancer	LC	107-30-2	27-Feb-87	<a href="#">0.3</a>
3-Chloro-2-methylpropene	cancer	SQE	563-47-3	1-Jul-89	<a href="#">5</a>
1-Chloro-4-nitrobenzene	cancer	<a href="#">SQE</a>	100-00-5	29-Oct-99	
2-Chloronitrobenzene	cancer	<a href="#">LC</a>	88-73-3	13-Sep-19	
4-Chloro- <i>o</i> -phenylenediamine	cancer	SQE	95-83-0	1-Jan-88	<a href="#">40</a>
Chloroprene	cancer	<a href="#">AB</a>	126-99-8	2-Jun-00	
2-Chloropropionic acid <a href="#">[Basis for listing changed effective December 20, 2013]</a>	male	<a href="#">SQE</a>	598-78-7	7-Aug-09	
Chlorothalonil	cancer	SQE	1897-45-6	1-Jan-89	<a href="#">41</a>
<i>p</i> -Chloro- <i>o</i> -toluidine	cancer	AB	95-69-2	1-Jan-90	<a href="#">3</a>
<i>p</i> -Chloro- <i>o</i> -toluidine, strong acid salts of	cancer	<a href="#">AB</a>	---	15-May-98	
<i>p</i> -Chloro- <i>o</i> -toluidine, hydrochloride					<a href="#">3.3</a>
5-Chloro- <i>o</i> -toluidine and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Chlorotrianisene	cancer	FR	569-57-3	1-Sep-96	
<i>p</i> -chloro- $\alpha,\alpha,\alpha$ -trifluorotoluene ( <i>para</i> -Chlorobenzotrifluoride, PCBTF)	cancer	AB	98-56-6	28-Jun-19	<a href="#">23</a>
Chlorozotocin	cancer	AB	54749-90-5	1-Jan-92	<a href="#">0.003</a>
Chlorpyrifos	developmental	<a href="#">SQE</a>	2921-88-2	15-Dec-17	<a href="#">0.58 (oral and inhalation) 7.2 (dermal)</a>
<a href="#">Chlorsulfuron Delisted June 6, 2014 [Click here for the basis for delisting]</a>	<del>developmental, female, male</del>	<a href="#">AB</a>	<del>64902-72-3</del>	<del>14-May-99</del>	
Chromium (hexavalent compounds)	cancer	LC	---	27-Feb-87	0.001 (inhalation)
Chromium (hexavalent compounds)	developmental, female, male	<a href="#">SQE</a>	---	19-Dec-08	<a href="#">8.2 (oral)</a>
Chrysene	cancer	AB	218-01-9	1-Jan-90	<a href="#">0.35 (oral)</a>
C.I. Acid Red 114	cancer	AB	6459-94-5	1-Jul-92	
C.I. Basic Red 9 monohydrochloride	cancer	SQE	569-61-9	1-Jul-89	<a href="#">3</a>

C.I. Direct Blue 15	cancer	<a href="#">AB</a>	2429-74-5	26-Aug-97	
C.I. Direct Blue 218	cancer	<a href="#">AB</a>	28407-37-6	26-Aug-97	<a href="#">50</a>
C.I. Disperse Yellow 3	cancer	<a href="#">SQE</a>	2832-40-8	8-Feb-13	
C.I. Solvent Yellow 14	cancer	<a href="#">AB</a>	842-07-9	15-May-98	
Cyclosporin (Cyclosporin A; Cyclosporine)	cancer	AB	59865-13-3; 79217-60-0	1-Jan-92	
Cidofovir	cancer, developmental, female, male	<a href="#">FR</a>	113852-37-2	29-Jan-99	
Cinnamyl anthranilate	cancer	SQE	87-29-6	1-Jul-89	<a href="#">200</a>
Cisplatin	cancer	SQE	15663-27-1	1-Oct-88	
Citrus Red No. 2	cancer	LC	6358-53-8	1-Oct-89	
Cladribine	developmental	FR	4291-63-8	1-Sep-96	
Clarithromycin	developmental	<a href="#">FR</a>	81103-11-9	1-May-97	
Clobetasol propionate	developmental, female	<a href="#">FR</a>	25122-46-7	15-May-98	
Clofibrate	cancer	FR	637-07-0	1-Sep-96	
Clomiphene citrate	cancer	<a href="#">FR</a>	50-41-9	24-May-13	
Clomiphene citrate	developmental	FR	50-41-9	1-Apr-90	
Clorazepate dipotassium	developmental	FR	57109-90-7	1-Oct-92	
CMNP (pyrazachlor)	cancer	<a href="#">AB</a>	6814-58-0	25-Aug-15	
Coal-tar pitch	cancer	LC	---	17-Nov-23	
Cobalt metal powder	cancer	AB	7440-48-4	1-Jul-92	
Cobalt [II] oxide	cancer	AB	1307-96-6	1-Jul-92	
Cobalt sulfate	cancer	<a href="#">LC</a>	10124-43-3	20-May-05	
Cobalt sulfate heptahydrate	cancer	<a href="#">AB</a>	10026-24-1	2-Jun-00	
Cocaine	developmental, female	SQE	50-36-2	1-Jul-89	
Coconut oil diethanolamine condensate (cocamide diethanolamine)	cancer	<a href="#">LC</a>	---	22-Jun-12	
Codeine phosphate	developmental	<a href="#">FR</a>	52-28-8	15-May-98	
Coke oven emissions	cancer	LC	---	27-Feb-87	0.3
Colchicine	developmental, male	FR	64-86-8	1-Oct-92	
Conjugated estrogens	cancer	LC	---	27-Feb-87	
Conjugated estrogens	developmental	FR	---	1-Apr-90	
Creosotes	cancer	SQE	---	1-Oct-88	
<i>p</i> -Cresidine	cancer	SQE	120-71-8	1-Jan-88	<a href="#">5</a>
Cumene	cancer	<a href="#">AB</a>	98-82-8	6-Apr-10	
Cupferron	cancer	SQE	135-20-6	1-Jan-88	<a href="#">3</a>
Cyanazine	developmental	FR	21725-46-2	1-Apr-90	
Cycasin	cancer	SQE	14901-08-7	1-Jan-88	
Cycloate	developmental	<a href="#">AB</a>	1134-23-2	19-Mar-99	

<a href="#">Cyclohexanol Delisted January 25, 2002</a> <a href="#">[Click here for the basis for delisting]</a>	male-	AB	108-93-0	6-Nov-98	
Cycloheximide	developmental	FR	66-81-9	1-Jan-89	
Cyclopenta[cd]pyrene	cancer	LC	27208-37-3	29-Apr-11	
Cyclophosphamide (anhydrous)	cancer	LC	50-18-0	27-Feb-87	<a href="#">1</a>
Cyclophosphamide (anhydrous)	developmental, female, male	SQE - developmental FR - female, male	50-18-0	1-Jan-89	
Cyclophosphamide (hydrated)	cancer	LC	6055-19-2	27-Feb-87	<a href="#">1</a>
Cyclophosphamide (hydrated)	developmental, female, male	SQE - developmental FR - female, male	6055-19-2	1-Jan-89	
Cyhexatin	developmental	FR	13121-70-5	1-Jan-89	
Cytarabine	developmental	SQE	147-94-4	1-Jan-89	
Cytembena	cancer	AB	21739-91-3	15-May-98	
D&C Orange No. 17	cancer	AB	3468-63-1	1-Jul-90	
D&C Red No. 8	cancer	AB	2092-56-0	1-Oct-90	
D&C Red No. 9	cancer	AB	2/1/5160	1-Jul-90	<a href="#">100</a>
D&C Red No. 19	cancer	AB	81-88-9	1-Jul-90	
Dacarbazine	cancer	SQE	3/4/4342	1-Jan-88	<a href="#">0.01</a>
Dacarbazine	developmental	FR	3/4/4342	29-Jan-99	
Daminozide	cancer	AB	1596-84-5	1-Jan-90	<a href="#">40</a>
Danazol	developmental	FR	17230-88-5	1-Apr-90	
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	cancer	AB	117-10-2	1-Jan-92	<a href="#">9</a>
Daunomycin	cancer	SQE	20830-81-3	1-Jan-88	
Daunorubicin hydrochloride	developmental	FR	23541-50-6	1-Jul-90	
<a href="#">2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001]</a>	developmental, male	AB	94-82-6	18-Jun-99	<a href="#">910</a>
DDD (Dichlorodiphenyl-dichloroethane)	cancer	SQE	72-54-8	1-Jan-89	2 (DDT, DDE, DDD in combination)
DDE (Dichlorodiphenyl-dichloroethylene)	cancer	SQE	72-55-9	1-Jan-89	2 (DDT, DDE, DDD in combination)
DDT (Dichlorodiphenyl-trichloroethane)	cancer	SQE	50-29-3	1-Oct-87	2 (DDT, DDE, DDD in combination)
o,p'-DDT	developmental, female, male	AB	789-02-6	15-May-98	

p,p'-DDT	developmental, female, male	<a href="#">AB</a>	50-29-3	15-May-98	
DDVP (Dichlorvos)	cancer	SQE	62-73-7	1-Jan-89	2
Demeclocycline hydrochloride (internal use)	developmental	FR	64-73-3	1-Jan-92	
Des-ethyl atrazine (DEA)	developmental, female	<a href="#">AB</a>	6190-65-4	15-Jul-16	<a href="#">100 (oral)</a>
Des-isopropyl atrazine (DIA)	developmental, female	<a href="#">AB</a>	1007-28-9	15-Jul-16	<a href="#">100 (oral)</a>
N,N'-Diacetylbenzidine	cancer	LC	613-35-4	1-Oct-89	
2,4-Diaminoanisole	cancer	FR	615-05-4	1-Oct-90	<a href="#">30</a>
2,4-Diaminoanisole sulfate	cancer	SQE	39156-41-7	1-Jan-88	<a href="#">50</a>
2,4-Diamino-6-chloro-s-triazine (DACT)	developmental, female	<a href="#">AB</a>	3397-62-4	15-Jul-16	<a href="#">100 (oral)</a>
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	cancer	SQE	101-80-4	1-Jan-88	<a href="#">5</a>
2,4-Diaminotoluene	cancer	SQE	95-80-7	1-Jan-88	<a href="#">0.2</a>
<a href="#">Diaminotoluene (mixed) Delisted November, 20 2015 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">AB</a>	---	<a href="#">1-Jan-90</a>	
Diazepam	developmental	FR	439-14-5	1-Jan-92	
Diazoaminobenzene	cancer	<a href="#">LC</a>	136-35-6	20-May-05	
Diazoxide	developmental	<a href="#">FR</a>	364-98-7	27-Feb-01	
Dibenz[a,h]acridine	cancer	SQE	226-36-8	1-Jan-88	
Dibenz[a,j]acridine	cancer	SQE	224-42-0	1-Jan-88	
Dibenzanthracenes	cancer	<a href="#">SQE</a>	---	26-Dec-14	
Dibenz[a,c]anthracene	cancer	<a href="#">SQE</a>	215-58-7	26-Dec-14	
Dibenz[a,h]anthracene	cancer	SQE	53-70-3	1-Jan-88	<a href="#">0.2</a>
Dibenz[a,j]anthracene	cancer	<a href="#">SQE</a>	224-41-9	26-Dec-14	
7H-Dibenzo[c,g]carbazole	cancer	SQE	194-59-2	1-Jan-88	<a href="#">0.0030 (oral)</a>
Dibenzo[a,e]pyrene	cancer	SQE	192-65-4	1-Jan-88	
Dibenzo[a,h]pyrene	cancer	SQE	189-64-0	1-Jan-88	<a href="#">0.0054 (oral)</a>
Dibenzo[a,i]pyrene	cancer	SQE	189-55-9	1-Jan-88	<a href="#">0.0050 (oral)</a>
Dibenzo[a,l]pyrene	cancer	SQE	191-30-0	1-Jan-88	
Dibromoacetic acid	cancer	<a href="#">AB</a>	631-64-1	17-Jun-08	<a href="#">2.8</a>
Dibromoacetonitrile	cancer	<a href="#">AB</a>	3252-43-5	3-May-11	
1,2-Dibromo-3-chloropropane (DBCP)	cancer	FR	96-12-8	1-Jul-87	0.1
1,2-Dibromo-3-chloropropane (DBCP) <a href="#">[Basis for listing changed effective November 22, 2013]</a>	male	<a href="#">FR</a>	96-12-8	27-Feb-87	<a href="#">3.1 (oral)</a> <a href="#">4.3 (inhalation)</a>
2,3-Dibromo-1-propanol	cancer	<a href="#">AB</a>	96-13-9	1-Oct-94	
Dichloroacetic acid	cancer	<a href="#">AB</a>	79-43-6	1-May-96	<a href="#">17</a>
Dichloroacetic acid	developmental, male	<a href="#">AB</a>	79-43-6	7-Aug-09	
p-Dichlorobenzene	cancer	SQE	106-46-7	1-Jan-89	20
3,3'-Dichlorobenzidine	cancer	SQE	91-94-1	1-Oct-87	0.6
3,3'-Dichlorobenzidine dihydrochloride	cancer	<a href="#">AB</a>	612-83-9	15-May-98	
1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE)	developmental, male	<a href="#">AB</a>	72-55-9	30-Mar-10	

1,4-Dichloro-2-butene	cancer	AB	764-41-0	1-Jan-90	
3,3'-Dichloro-4,4'-diamino-diphenyl ether	cancer	SQE	28434-86-8	1-Jan-88	
1,1-Dichloroethane	cancer	AB	75-34-3	1-Jan-90	<a href="#">100</a>
Dichloromethane (Methylene chloride)	cancer	SQE	75-09-2	1-Apr-88	50 200 (inhalation)
1,4-Dichloro-2-nitrobenzene	cancer	<a href="#">LC</a>	89-61-2	13-Sep-19	
2,4-Dichloro-1-nitrobenzene	cancer	<a href="#">LC</a>	611-06-3	13-Sep-19	
Dichlorophene	developmental	<a href="#">AB</a>	97-23-4	27-Apr-99	
Dichlorophenamide	developmental	<a href="#">FR</a>	120-97-8	27-Feb-01	
1,2-Dichloropropane	cancer	AB	78-87-5	1-Jan-90	<a href="#">9.7</a>
1,3-Dichloro-2-propanol (1,3-DCP)	cancer	<a href="#">SQE</a>	96-23-1	8-Oct-10	
1,3-Dichloropropene	cancer	SQE	542-75-6	1-Jan-89	<a href="#">3.7 (oral and inhalation)</a>
Diclofop-methyl	cancer	<a href="#">AB</a>	51338-27-3	6-Apr-10	
Diclofop methyl	developmental	<a href="#">AB</a>	51338-27-3	5-Mar-99	
Dicumarol	developmental	FR	66-76-2	1-Oct-92	
Dieldrin	cancer	SQE	60-57-1	1-Jul-88	0.04
<a href="#">Dienestrol Delisted January 4, 2013</a> <a href="#">[Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">LC</a>	<a href="#">84-17-3</a>	<a href="#">1-Jan-90</a>	
Diepoxybutane	cancer	SQE	1464-53-5	1-Jan-88	
Diesel engine exhaust	cancer	AB	---	1-Oct-90	
Diethanolamine	cancer	<a href="#">LC</a>	111-42-2	22-Jun-12	
Di(2-ethylhexyl)phthalate (DEHP)	cancer	SQE	117-81-7	1-Jan-88	<a href="#">310</a>
Di(2-ethylhexyl)phthalate (DEHP)	developmental, male	<a href="#">AB</a>	117-81-7	24-Oct-03	
Adult <sup>b</sup>					<a href="#">4200 (intravenous)</a>
Infant boys, age 29 days to 24 months <sup>b</sup>					<a href="#">600 (intravenous)</a>
Neonatal infant boys, age 0 to 28 days <sup>b</sup>					<a href="#">210 (intravenous)</a>
Adult <sup>b</sup>					<a href="#">410 (oral)</a>
Infant boys, age 29 days to 24 months <sup>b</sup>					<a href="#">58 (oral)</a>
Neonatal infant boys, age 0 to 28 days <sup>b</sup>					<a href="#">20 (oral)</a>
1,2-Diethylhydrazine	cancer	SQE	1615-80-1	1-Jan-88	
Diethylstilbestrol (DES)	cancer	LC	56-53-1	27-Feb-87	<a href="#">0.002</a>
Diethylstilbestrol (DES)	developmental	FR	56-53-1	1-Jul-87	
Diethyl sulfate	cancer	SQE	64-67-5	1-Jan-88	
Diflunisal	developmental, female	<a href="#">FR</a>	22494-42-4	29-Jan-99	
<a href="#">Diglycidyl ether Delisted April 4, 2014</a> <a href="#">[Click here for the basis for delisting]</a>	<a href="#">male</a>	<a href="#">LC</a>	<a href="#">7/5/2238</a>	<a href="#">7-Aug-09</a>	
Diglycidyl resorcinol ether (DGRE)	cancer	SQE	101-90-6	1-Jul-89	<a href="#">0.4</a>

Dihydroergotamine mesylate	developmental	<a href="#">FR</a>	6190-39-2	1-May-97	
Dihydrosafrole	cancer	SQE	94-58-6	1-Jan-88	<a href="#">20</a>
Di-isodecyl phthalate (DIDP)	developmental	<a href="#">AB</a>	68515-49-1/ 26761-40-0	20-Apr-07	<a href="#">2200</a>
Diisononyl phthalate (DINP)	cancer	<a href="#">SQE</a>	---	20-Dec-13	<a href="#">146</a>
Diisopropyl sulfate	cancer	AB	10/6/2973	1-Apr-93	
Diltiazem hydrochloride	developmental	<a href="#">FR</a>	33286-22-5	27-Feb-01	
3,3'-Dimethoxybenzidine ( <i>o</i> -Dianisidine)	cancer	SQE	119-90-4	1-Jan-88	<a href="#">0.15</a>
3,3'-Dimethoxybenzidine dihydrochloride	cancer	AB	20325-40-0	1-Oct-90	<a href="#">0.19</a>
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine	cancer	<a href="#">AB</a>	---	11-Jun-04	
N,N-Dimethylacetamide	cancer	<a href="#">LC</a>	127-19-5	13-Sep-19	
<a href="#">N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013]</a>	developmental, male	<a href="#">SQE</a>	127-19-5	21-May-10	
4-Dimethylaminoazobenzene	cancer	SQE	60-11-7	1-Jan-88	<a href="#">0.2</a>
<i>trans</i> -2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	cancer	SQE	55738-54-0	1-Jan-88	<a href="#">2</a>
7,12-Dimethylbenz(a)anthracene	cancer	AB	57-97-6	1-Jan-90	<a href="#">0.003</a>
3,3'-Dimethylbenzidine (ortho-Tolidine)	cancer	SQE	119-93-7	1-Jan-88	<a href="#">0.044</a>
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine	cancer	<a href="#">AB</a>	---	11-Jun-04	
3,3'-Dimethylbenzidine dihydrochloride	cancer	AB	612-82-8	1-Apr-92	<a href="#">0.059</a>
Dimethylcarbamoyl chloride	cancer	SQE	79-44-7	1-Jan-88	<a href="#">0.05</a>
N,N-Dimethylformamide	cancer	<a href="#">LC</a>	68-12-2	27-Oct-17	
1,1-Dimethylhydrazine (UDMH)	cancer	LC	57-14-7	1-Oct-89	
1,2-Dimethylhydrazine	cancer	SQE	540-73-8	1-Jan-88	<a href="#">0.001</a>
Dimethyl hydrogen phosphite	cancer	<a href="#">LC</a>	868-85-9	11-Aug-23	
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	cancer	<a href="#">SQE</a>	1456-28-6	8-Feb-13	
Dimethyl sulfate	cancer	SQE	77-78-1	1-Jan-88	
<i>N,N</i> -Dimethyl- <i>p</i> -toluidine	cancer	<a href="#">AB</a>	99-97-8	2-May-14	
Dimethylvinylchloride	cancer	SQE	513-37-1	1-Jul-89	<a href="#">20</a>
Di- <i>n</i> -butyl phthalate (DBP)	developmental, female, male	<a href="#">AB</a>	84-74-2	2-Dec-05	<a href="#">8.7</a>
Di- <i>n</i> -hexyl phthalate (DnHP)	female, male	<a href="#">AB</a>	84-75-3	2-Dec-05	<a href="#">2200 (oral)</a>
<i>m</i> -Dinitrobenzene	male	AB	99-65-0	1-Jul-90	<a href="#">38</a>
<i>o</i> -Dinitrobenzene	male	AB	528-29-0	1-Jul-90	
<i>p</i> -Dinitrobenzene	male	AB	100-25-4	1-Jul-90	
3,7-Dinitrofluoranthene	cancer	<a href="#">AB</a>	105735-71-5	26-Aug-97	
3,9-Dinitrofluoranthene	cancer	<a href="#">AB</a>	22506-53-2	26-Aug-97	

1,3-Dinitropyrene	cancer	<a href="#">LC</a>	75321-20-9	2-Nov-12	
1,6-Dinitropyrene	cancer	AB	42397-64-8	1-Oct-90	
1,8-Dinitropyrene	cancer	AB	42397-65-9	1-Oct-90	
2,4-Dinitrotoluene	cancer	SQE	121-14-2	1-Jul-88	2
2,4-Dinitrotoluene	male	<a href="#">AB</a>	121-14-2	20-Aug-99	
2,6-Dinitrotoluene	cancer	SQE	606-20-2	1-Jul-95	
2,6-Dinitrotoluene	male	<a href="#">AB</a>	606-20-2	20-Aug-99	
Dinitrotoluene (technical grade)	female, male	<a href="#">AB</a>	---	20-Aug-99	
Dinitrotoluene mixture, 2,4-/2,6-	cancer	AB	---	1-May-96	
Dinocap	developmental	FR	39300-45-3	1-Apr-90	
Dinoseb	developmental, male	FR	88-85-7	1-Jan-89	
Di- <i>n</i> -propyl isocinchomeronate (MGK Repellent 326)	cancer	AB	136-45-8	1-May-96	
1,4-Dioxane	cancer	SQE	123-91-1	1-Jan-88	30
Diphenylhydantoin (Phenytoin)	cancer	SQE	57-41-0	1-Jan-88	
Diphenylhydantoin (Phenytoin)	developmental	SQE	57-41-0	1-Jul-87	
Diphenylhydantoin (Phenytoin), sodium salt	cancer	SQE	630-93-3	1-Jan-88	
Direct Black 38 (technical grade)	cancer	SQE	1937-37-7	1-Jan-88	<a href="#">0.09</a>
Direct Blue 6 (technical grade)	cancer	SQE	2602-46-2	1-Jan-88	<a href="#">0.09</a>
Direct Brown 95 (technical grade)	cancer	SQE	16071-86-6	1-Oct-88	<a href="#">0.1</a>
Disodium cyanodithioimidocarbonate	developmental	<a href="#">AB</a>	138-93-2	30-Mar-99	<a href="#">56 (oral)</a> <a href="#">170 (oral) as 32% pesticide formulation</a>
Disperse Blue 1	cancer	AB	2475-45-8	1-Oct-90	<a href="#">200</a>
Diuron	cancer	<a href="#">AB</a>	330-54-1	31-May-02	
Doxorubicin hydrochloride (Adriamycin)	cancer	SQE	25316-40-9	1-Jul-87	
Doxorubicin hydrochloride (Adriamycin)	developmental, male	<a href="#">FR</a>	25316-40-9	29-Jan-99	
Doxycycline (internal use)	developmental	FR	564-25-0	1-Jul-90	
Doxycycline calcium (internal use)	developmental	FR	94088-85-4	1-Jan-92	
Doxycycline hyclate (internal use)	developmental	FR	24390-14-5	1-Oct-91	
Doxycycline monohydrate (internal use)	developmental	FR	17086-28-1	1-Oct-91	
<a href="#">2,4-DP (dichloroprop) Delisted January 25, 2002 [Click here for the basis for delisting]</a>	<del>developmental</del>	<del>AB</del>	<del>120-36-5</del>	<del>27-Apr-99</del>	
Emissions from combustion of coal	cancer	<a href="#">AB</a>	---	7-Aug-13	
Emissions from high-temperature unrefined rapeseed oil	cancer	<a href="#">AB</a>	---	3-Jan-14	
Endrin	developmental	<a href="#">AB</a>	72-20-8	15-May-98	

Environmental tobacco smoke (ETS)	developmental	<a href="#">SQE</a>	---	9-Jun-06	
Epichlorohydrin	cancer	<a href="#">SQE</a>	106-89-8	1-Oct-87	9
Epichlorohydrin	male	<a href="#">AB</a>	106-89-8	1-Sep-96	
Epoxiconazole	cancer	<a href="#">AB</a>	135319-73-2	15-Apr-11	
Ergotamine tartrate	developmental	<a href="#">FR</a>	379-79-3	1-Apr-90	
Erionite	cancer	<a href="#">SQE</a>	12510-42-8; 66733-21-9	1-Oct-88	
Estradiol 17B	cancer	<a href="#">SQE</a>	50-28-2	1-Jan-88	<a href="#">0.02</a>
Estragole	cancer	<a href="#">SQE</a>	140-67-0	29-Oct-99	
Estrogens, steroidal	cancer	<a href="#">LC</a>	---	19-Aug-05	
Estrogen-progestogen (combined) used as menopausal therapy	cancer	<a href="#">LC</a>	---	4-Nov-11	
Estrone	cancer	<a href="#">SQE</a>	53-16-7	1-Jan-88	
Estropipate	cancer, developmental	<a href="#">FR</a>	7280-37-7	26-Aug-97	
Ethinylestradiol	cancer	<a href="#">SQE</a>	57-63-6	1-Jan-88	
Ethionamide	developmental	<a href="#">FR</a>	536-33-4	26-Aug-97	
Ethoprop	cancer	<a href="#">AB</a>	13194-48-4	27-Feb-01	
Ethyl acrylate	cancer	<a href="#">SQE</a>	140-88-5	1-Jul-89	
Ethyl alcohol in alcoholic beverages	developmental	<a href="#">SQE</a>	---	1-Oct-87	
Ethylbenzene	cancer	<a href="#">AB</a>	100-41-4	11-Jun-04	<a href="#">54 (inhalation)</a> <a href="#">41 (oral)</a>
<a href="#">Ethyl-tert-butyl ether Delisted December 13, 2013 [Click here for the basis for delisting]</a>	male-	<a href="#">LC</a>	<a href="#">637-92-3</a>	<a href="#">18-Dec-09</a>	
Ethyl dipropylthiocarbamate	developmental	<a href="#">AB</a>	759-94-4	27-Apr-99	<a href="#">700 (oral and inhalation)</a> <a href="#">6700 (dermal)</a>
Ethyl-4,4'-dichlorobenzilate	cancer	<a href="#">AB</a>	510-15-6	1-Jan-90	<a href="#">7</a>
Ethylene dibromide	cancer	<a href="#">FR</a>	106-93-4	1-Jul-87	<a href="#">0.2 (oral)</a> <a href="#">3 (inhalation)</a>
Ethylene dibromide	developmental, male	<a href="#">AB</a>	106-93-4	15-May-98	
Ethylene dichloride (1,2-Dichloroethane)	cancer	<a href="#">SQE</a>	107-06-2	1-Oct-87	10
Ethylene glycol (ingested)	developmental	<a href="#">AB</a>	107-21-1	19-Jun-15	<a href="#">8700 (oral)</a>
Ethylene glycol monoethyl ether	developmental, male	<a href="#">SQE</a>	110-80-5	1-Jan-89	<a href="#">750 (oral)</a> <a href="#">960 (inhalation)</a>
Ethylene glycol monoethyl ether acetate	developmental, male	<a href="#">AB</a>	111-15-9	1-Jan-93	<a href="#">1100 (oral)</a> <a href="#">1400 (inhalation)</a>
Ethylene glycol monomethyl ether	developmental, male	<a href="#">SQE</a>	109-86-4	1-Jan-89	<a href="#">63 (oral)</a>
Ethylene glycol monomethyl ether acetate	developmental, male	<a href="#">AB</a>	110-49-6	1-Jan-93	<a href="#">98 (oral)</a>
Ethyleneimine (Aziridine)	cancer	<a href="#">SQE</a>	151-56-4	1-Jan-88	<a href="#">0.01</a>
Ethylene oxide	cancer	<a href="#">FR</a>	75-21-8	1-Jul-87	2

<a href="#">Ethylene oxide [Basis for listing changed effective November 22, 2013]</a>	female	<a href="#">FR</a>	75-21-8	27-Feb-87	20
<a href="#">Ethylene oxide [Basis for listing changed effective November 22, 2013]</a>	developmental, male	<a href="#">FR</a>	75-21-8	7-Aug-09	20
Ethylene thiourea	cancer	AB	96-45-7	1-Jan-88	<a href="#">20</a>
Ethylene thiourea	developmental	SQE	96-45-7	1-Jan-93	
<a href="#">2-Ethylhexanoic acid Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	<a href="#">LC</a>	<a href="#">149-57-5</a>	<a href="#">7-Aug-09</a>	
2-Ethylhexyl acrylate	cancer	<a href="#">LC</a>	103-11-7	17-Dec-21	
Ethyl methanesulfonate	cancer	SQE	62-50-0	1-Jan-88	
Etodolac	developmental, female	<a href="#">FR</a>	41340-25-4	20-Aug-99	
Etoposide	cancer	<a href="#">LC</a>	33419-42-0	4-Nov-11	
Etoposide	developmental	FR	33419-42-0	1-Jul-90	
Etoposide in combination with cisplatin and bleomycin	cancer	<a href="#">LC</a>	---	4-Nov-11	
Etretinate	developmental	SQE	54350-48-0	1-Jul-87	
Fenoxaprop ethyl	developmental	<a href="#">AB</a>	66441-23-4	26-Mar-99	
Fenoxycarb	cancer	<a href="#">AB</a>	72490-01-8	2-Jun-00	
Filgrastim	developmental	<a href="#">FR</a>	121181-53-1	27-Feb-01	
Fluazifop butyl	developmental	<a href="#">AB</a>	69806-50-4	6-Nov-98	
Flunisolide	developmental, female	<a href="#">FR</a>	3/3/3385	15-May-98	
Fluorouracil	developmental	SQE	51-21-8	1-Jan-89	
Fluoro-edenite fibrous amphibole	cancer	LC	---	17-Nov-23	
Fluoxymesterone	developmental	FR	76-43-7	1-Apr-90	
Flurazepam hydrochloride	developmental	FR	1172-18-5	1-Oct-92	
Flurbiprofen	developmental, female	<a href="#">FR</a>	5104-49-4	20-Aug-99	
Flutamide	developmental	FR	13311-84-7	1-Jul-90	
Fluticasone propionate	developmental	<a href="#">FR</a>	80474-14-2	15-May-98	
Fluvalinate	developmental	<a href="#">AB</a>	69409-94-5	6-Nov-98	
Folpet	cancer	SQE	133-07-3	1-Jan-89	200
Formaldehyde (gas)	cancer	SQE	50-00-0	1-Jan-88	40
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole	cancer	SQE	3570-75-0	1-Jan-88	<a href="#">0.3</a>
Fumonisin B <sub>1</sub>	cancer	<a href="#">AB</a>	116355-83-0	14-Nov-03	

Furan	cancer	AB	110-00-9	1-Oct-93	
Furazolidone	cancer	AB	67-45-8	1-Jan-90	
Furfuryl alcohol	cancer	<a href="#">AB</a>	98-00-0	30-Sep-16	
Furmecyclox	cancer	AB	60568-05-0	1-Jan-90	20
Fusarin C	cancer	SQE	79748-81-5	1-Jul-95	
Gallium arsenide	cancer	<a href="#">LC</a>	1303-00-0	1-Aug-08	
	cancer, developmental, male				
Ganciclovir		<a href="#">FR</a>	82410-32-0	26-Aug-97	
	developmental, male				
Ganciclovir sodium		<a href="#">FR</a>	107910-75-8	26-Aug-97	
Gasoline engine exhaust (condensates/extracts)	cancer	AB	---	1-Oct-90	
Gemfibrozil	cancer	<a href="#">FR</a>	25812-30-0	22-Dec-00	
Gemfibrozil	female, male	<a href="#">FR</a>	25812-30-0	20-Aug-99	
Gentian violet (Crystal violet)	cancer	SQE	548-62-9	23-Nov-18	
Glass wool fibers (inhalable and biopersistent)	cancer	AB	---	1-Jul-90	
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-11-4	1-Jan-90	<a href="#">0.1</a>
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)	cancer	AB	67730-10-3	1-Jan-90	<a href="#">0.5</a>
Glycidaldehyde	cancer	SQE	765-34-4	1-Jan-88	
Glycidol	cancer	AB	556-52-5	1-Jul-90	<a href="#">0.54</a>
Glycidyl methacrylate	cancer	<a href="#">LC</a>	106-91-2	27-Jan-23	
Glyphosate	cancer	<a href="#">LC</a>	1071-83-6	7-Jul-17	<a href="#">1100</a>
Goldenseal root powder	cancer	<a href="#">LC</a>	---	4-Dec-15	
	developmental, female, male				
Goserelin acetate		<a href="#">FR</a>	65807-02-5	26-Aug-97	
Griseofulvin	cancer	AB	126-07-8	1-Jan-90	
Gyromitrin (Acetaldehyde methylformylhydrazone)	cancer	SQE	16568-02-8	1-Jan-88	<a href="#">0.07</a>
	developmental				
Halazepam		FR	23092-17-3	1-Jul-90	
	developmental				
Halobetasol propionate		<a href="#">FR</a>	66852-54-8	20-Aug-99	
	developmental, female				
Haloperidol		<a href="#">FR</a>	52-86-8	29-Jan-99	
	developmental				
Halothane		FR	151-67-7	1-Sep-96	
HC Blue 1	cancer	SQE	2784-94-3	1-Jul-89	<a href="#">10</a>
Heptachlor	cancer	SQE	76-44-8	1-Jul-88	0.2
	developmental				
Heptachlor		<a href="#">AB</a>	76-44-8	20-Aug-99	
Heptachlor epoxide	cancer	SQE	1024-57-3	1-Jul-88	0.08
Herbal remedies containing plant species of the genus <i>Aristolochia</i>	cancer	<a href="#">LC</a>	---	9-Jul-04	
Hexachlorobenzene	cancer	SQE	118-74-1	1-Oct-87	0.4

Hexachlorobenzene	developmental	SQE	118-74-1	1-Jan-89	
Hexachlorobutadiene	cancer	AB	87-68-3	3-May-11	
Hexachlorocyclohexane (technical grade)	cancer	SQE	---	1-Oct-87	0.2
Hexachlorocyclohexane (alpha isomer)					0.3
Hexachlorocyclohexane (beta isomer)					0.5
Hexachlorocyclohexane (gamma isomer)					0.6
Hexachlorodibenzodioxin	cancer	SQE	34465-46-8	1-Apr-88	0.0002
Hexachloroethane	cancer	AB	67-72-1	1-Jul-90	20
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	cancer	AB	---	4-Mar-05	
Hexafluoroacetone [Basis for listing changed effective June 6, 2014]	developmental, male	LC SQE	684-16-2	1-Aug-08	
Hexamethylphosphoramide	cancer	SQE	680-31-9	1-Jan-88	
Hexamethylphosphoramide	male	AB	680-31-9	1-Oct-94	
n-Hexane	male	SQE	110-54-3	15-Dec-17	28,000 (oral) 20,000 (inhalation)
2,5-Hexanedione	male	SQE	110-13-4	4-Dec-15	
Histrelin acetate	developmental	FR	---	15-May-98	
Hydramethylnon	developmental, male	AB	67485-29-4	5-Mar-99	120 (oral)
Hydrazine	cancer	SQE	302-01-2	1-Jan-88	0.04
Hydrazine sulfate	cancer	SQE	10034-93-2	1-Jan-88	0.2
Hydrazobenzene (1,2-Diphenylhydrazine)	cancer	SQE	122-66-7	1-Jan-88	0.8
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male	AB	---	5-Jul-13	
Cyanide salts that readily dissociate in solution (expressed as cyanide) <sup>f</sup>					9.8
Hydrogen cyanide <sup>f</sup>					10 (oral)
Sodium cyanide <sup>f</sup>					19 (oral)
Potassium cyanide <sup>f</sup>					25 (oral)
1-Hydroxyanthraquinone	cancer	LC	129-43-1	27-May-05	
Hydroxyurea	developmental	FR	127-07-1	1-May-97	
Idarubicin hydrochloride	developmental, male	FR	57852-57-0	20-Aug-99	
Ifosfamide	developmental	FR	3778-73-2	1-Jul-90	
Iodine-131	developmental	SQE	10043-66-0	1-Jan-89	
Imazalil	cancer	AB	35554-44-0	20-May-11	11
Indeno[1,2,3-cd]pyrene	cancer	SQE	193-39-5	1-Jan-88	
Indium phosphide	cancer	AB	22398-80-7	27-Feb-01	
Indium tin oxide	cancer	LC	50926-11-9	19-Mar-21	

IQ (2-Amino-3-methylimidazo[4,5-f] quinoline)	cancer	AB	76180-96-6	1-Apr-90	<a href="#">0.5</a>
Iprodione	cancer	AB	36734-19-7	1-May-96	
Iprovalicarb	cancer	<a href="#">AB</a>	140923-17-7/ 140923-25-7	1-Jun-07	
Iron dextran complex	cancer	SQE	9004-66-4	1-Jan-88	
Isobutyl nitrite	cancer	AB	542-56-3	1-May-96	<a href="#">7.4</a>
Isoprene	cancer	AB	78-79-5	1-May-96	
Isopyrazam	cancer	<a href="#">AB</a>	881685-58-1	24-Jul-12	
<a href="#">Isosafrole Delisted December 8, 2006</a> <a href="#">[Click here for the basis for delisting]</a>	<del>cancer</del>	<del>LC</del>	<del>120-58-1</del>	<del>1-Oct-89</del>	
Isotretinoin	developmental	SQE	4759-48-2	1-Jul-87	
Isoxaflutole	cancer	<a href="#">AB</a>	141112-29-0	22-Dec-00	
Kresoxim-methyl	cancer	<a href="#">AB</a>	143390-89-0	3-Feb-12	
Lactofen	cancer	SQE	77501-63-4	1-Jan-89	
Lasiocarpine	cancer	SQE	303-34-4	1-Apr-88	<a href="#">0.09</a>
Lead <a href="#">[Basis for listing changed effective November 22, 2013]</a>	developmental, female, male	<a href="#">FR</a>	---	27-Feb-87	0.5
Lead and lead compounds	cancer	AB	---	1-Oct-92	
Lead					<a href="#">15 (oral)</a>
Lead acetate	cancer	SQE	301-04-2	1-Jan-88	<a href="#">23 (oral)</a>
Lead phosphate	cancer	SQE	7446-27-7	1-Apr-88	<a href="#">58 (oral)</a>
Lead subacetate	cancer	LC	1335-32-6	1-Oct-89	<a href="#">41 (oral)</a>
Leather dust	cancer	<a href="#">LC</a>	---	29-Apr-11	
Leucomalachite green	cancer	<a href="#">LC</a>	129-73-7	21-Apr-23	
Leuprolide acetate	developmental, female, male	<a href="#">FR</a>	74381-53-6	26-Aug-97	
Levodopa	developmental	<a href="#">FR</a>	59-92-7	29-Jan-99	
Levonorgestrel implants	female	<a href="#">FR</a>	797-63-7	15-May-98	
Lindane and other hexachlorocyclohexane isomers	cancer	LC	---	1-Oct-89	
Linuron	developmental	<a href="#">AB</a>	330-55-2	19-Mar-99	<a href="#">460</a>
Lithium carbonate	developmental	FR	554-13-2	1-Jan-91	
Lithium citrate	developmental	FR	919-16-4	1-Jan-91	
Lorazepam	developmental	FR	846-49-1	1-Jul-90	
Lovastatin	developmental	FR	75330-75-5	1-Oct-92	
Lynestrenol	cancer	<a href="#">AB</a>	52-76-6	27-Feb-01	
Malathion	cancer	<a href="#">LC</a>	121-75-5	20-May-16	<a href="#">180</a>

Malonaldehyde, sodium salt	cancer	<a href="#">AB</a>	24382-04-5	3-May-11	
Mancozeb	cancer	AB	1/7/8018	1-Jan-90	
Maneb	cancer	AB	12427-38-2	1-Jan-90	
Marijuana smoke	cancer	<a href="#">SQE</a>	---	19-Jun-09	
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	cancer	AB	68006-83-7	1-Jan-90	<a href="#">0.6</a>
Mebendazole	developmental	<a href="#">FR</a>	31431-39-7	20-Aug-99	
Medroxyprogesterone acetate	cancer	AB	71-58-9	1-Jan-90	
Medroxyprogesterone acetate	developmental	FR	71-58-9	1-Apr-90	
Megestrol acetate	cancer	<a href="#">FR</a>	595-33-5	28-Mar-14	
Megestrol acetate	developmental	FR	595-33-5	1-Jan-91	
MelQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)	cancer	AB	77094-11-2	1-Oct-94	<a href="#">0.46</a>
MelQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	cancer	AB	77500-04-0	1-Oct-94	<a href="#">0.41</a>
Melphalan	cancer	LC	148-82-3	27-Feb-87	<a href="#">0.005</a>
Melphalan	developmental	FR	148-82-3	1-Jul-90	
Menotropins	developmental	FR	9002-68-0	1-Apr-90	
Mepanipirim	cancer	<a href="#">AB</a>	110235-47-7	1-Jul-08	
Meproamate	developmental	FR	57-53-4	1-Jan-92	
2-Mercaptobenzothiazole	cancer	<a href="#">LC</a>	149-30-4	27-Oct-17	
Mercaptopurine	developmental	FR	6112-76-1	1-Jul-90	
Mercury and mercury compounds	developmental	AB	---	1-Jul-90	
Merphalan	cancer	SQE	531-76-0	1-Apr-88	
Mestranol	cancer	SQE	72-33-3	1-Apr-88	
Metam potassium	cancer	<a href="#">AB</a>	137-41-7	31-Dec-10	
Methacycline hydrochloride	developmental	FR	3963-95-9	1-Jan-91	
Metham sodium	cancer	<a href="#">AB</a>	137-42-8	6-Nov-98	
Metham sodium	developmental	<a href="#">AB</a>	137-42-8	15-May-98	<a href="#">290</a>
Methanol	developmental	<a href="#">AB</a>	67-56-1	16-Mar-12	<a href="#">47,000 (inhalation)</a> <a href="#">23,000 (oral)</a>
Methazole	developmental	<a href="#">AB</a>	20354-26-1	1-Dec-99	
Methimazole	developmental	FR	60-56-0	1-Jul-90	
Methotrexate	developmental	SQE	59-05-2	1-Jan-89	
Methotrexate sodium	developmental	FR	15475-56-6	1-Apr-90	
5-Methoxypsoralen with ultraviolet A therapy	cancer	SQE	484-20-8	1-Oct-88	

8-Methoxypsoralen with ultraviolet A therapy	cancer	LC	298-81-7	27-Feb-87	
Methyl acrylate	cancer	<a href="#">LC</a>	96-33-3	17-Dec-21	
2-Methylaziridine (Propyleneimine)	cancer	SQE	75-55-8	1-Jan-88	<a href="#">0.028</a>
Methylazoxymethanol	cancer	SQE	590-96-5	1-Apr-88	
Methylazoxymethanol acetate	cancer	SQE	592-62-1	1-Apr-88	
Methyl bromide, as a structural fumigant	developmental	FR	74-83-9	1-Jan-93	<a href="#">810 (inhalation)</a>
Methyl carbamate	cancer	<a href="#">AB</a>	598-55-0	15-May-98	<a href="#">160</a>
Methyl chloride	developmental	<a href="#">AB</a>	74-87-3	10-Mar-00	
Methyl chloride [ <a href="#">Basis for listing changed effective March 7, 2014</a> ]	male	<a href="#">AB</a>	74-87-3	7-Aug-09	
3-Methylcholanthrene	cancer	AB	56-49-5	1-Jan-90	<a href="#">0.03</a>
5-Methylchrysene	cancer	SQE	3697-24-3	1-Apr-88	<a href="#">0.0084 (oral)</a>
4,4'-Methylene bis(2-chloroaniline)	cancer	FR	101-14-4	1-Jul-87	<a href="#">0.5</a>
4,4'-Methylene bis(N,N-dimethyl)benzenamine	cancer	LC	101-61-1	1-Oct-89	20
4,4'-Methylene bis(2-methylaniline)	cancer	SQE	838-88-0	1-Apr-88	<a href="#">0.8</a>
4,4'-Methylenedianiline	cancer	SQE	101-77-9	1-Jan-88	<a href="#">0.4</a>
4,4'-Methylenedianiline dihydrochloride	cancer	SQE	13552-44-8	1-Jan-88	<a href="#">0.6</a>
Methyleugenol	cancer	<a href="#">AB</a>	93-15-2	16-Nov-01	
Methylhydrazine and its salts	cancer	AB	---	1-Jul-92	
Methylhydrazine					<a href="#">0.058 (oral)</a> <a href="#">0.090 (inhalation)</a>
Methylhydrazine sulfate					<a href="#">0.18</a>
2-Methylimidazole	cancer	<a href="#">LC</a>	693-98-1	22-Jun-12	
4-Methylimidazole	cancer	<a href="#">AB</a>	822-36-6	7-Jan-11	<a href="#">29</a>
Methyl iodide	cancer	SQE	74-88-4	1-Apr-88	
Methyl isobutyl ketone	cancer	<a href="#">LC</a>	108-10-1	4-Nov-11	
Methyl isobutyl ketone (MIBK)	developmental	<a href="#">AB</a>	108-10-1	28-Mar-14	
Methyl isocyanate (MIC)	developmental, female	<a href="#">SQE</a>	624-83-9	12-Nov-10	
<a href="#">Methyl isopropyl ketone Delisted April 4, 2014 [Click for the basis for delisting]</a>	developmental	<a href="#">LC</a>	<del>563-80-4</del>	<del>17-Feb-12</del>	
Methyl mercury	developmental	SQE	---	1-Jul-87	
Methylmercury compounds	cancer	AB	---	1-May-96	
Methyl methanesulfonate	cancer	SQE	66-27-3	1-Apr-88	<a href="#">7</a>
Methyl-n-butyl ketone	developmental	<a href="#">SQE</a>	591-78-6	4-Dec-15	
Methyl-n-butyl ketone [ <a href="#">Basis for listing changed effective November 9, 2015</a> ]	male	SQE	591-78-6	7-Aug-09	
2-Methyl-1-nitroanthraquinone (of uncertain purity)	cancer	SQE	129-15-7	1-Apr-88	<a href="#">0.2</a>
N-Methyl-N'-nitro-N-nitrosoguanidine	cancer	SQE	70-25-7	1-Apr-88	<a href="#">0.08</a>
N-Methylolacrylamide	cancer	AB	924-42-5	1-Jul-90	

N-Methylpyrrolidone	developmental	<a href="#">AB</a>	872-50-4	15-Jun-01	<a href="#">3200 (inhalation)</a> <a href="#">17000 (dermal)</a>
α-Methyl styrene (alpha-Methylstyrene)	cancer	<a href="#">LC</a>	98-83-9	2-Nov-12	
<a href="#">α-Methyl styrene Delisted April 4, 2014 [Click for the basis for delisting]</a>	female	<a href="#">LC</a>	<a href="#">98-83-9</a>	<a href="#">29-Jul-11</a>	
Methyltestosterone	developmental	FR	58-18-4	1-Apr-90	
Methylthiouracil	cancer	LC	56-04-2	1-Oct-89	<a href="#">2</a>
Metiram	cancer	AB	9006-42-2	1-Jan-90	
Metiram	developmental	<a href="#">AB</a>	9006-42-2	30-Mar-99	
Metronidazole	cancer	SQE	443-48-1	1-Jan-88	
Michler's ketone	cancer	SQE	90-94-8	1-Jan-88	<a href="#">0.8</a>
Midazolam hydrochloride	developmental	FR	59467-96-8	1-Jul-90	
Minocycline hydrochloride (internal use)	developmental	FR	13614-98-7	1-Jan-92	
Mirex	cancer	SQE	2385-85-5	1-Jan-88	<a href="#">0.04</a>
Misoprostol	developmental	FR	59122-46-2	1-Apr-90	
Mitomycin C	cancer	SQE	50-07-7	1-Apr-88	<a href="#">0.00009</a>
Mitoxantrone hydrochloride	cancer	<a href="#">FR</a>	70476-82-3	23-Jan-15	
Mitoxantrone hydrochloride	developmental	FR	70476-82-3	1-Jul-90	
Molinate	developmental, female, male	<a href="#">AB</a>	2212-67-1	11-Dec-09	
Molybdenum trioxide	cancer	<a href="#">LC</a>	1313-27-5	19-Mar-21	
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane)	cancer	<a href="#">AB</a>	71526-07-3	22-Mar-11	
MON 13900 (furilazole)	cancer	<a href="#">AB</a>	121776-33-8	22-Mar-11	
3-Monochloropropane-1,2-diol (3-MCPD)	cancer	<a href="#">SQE</a>	96-24-2	8-Oct-10	
Monocrotaline	cancer	SQE	315-22-0	1-Apr-88	<a href="#">0.07</a>
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	cancer	<a href="#">LC</a>	113803-47-7	4-Nov-11	
5-(Morpholinomethyl)-3-[(5-nitrofurfuryl-idene)-amino]-2-oxazolidinone	cancer	SQE	139-91-3	1-Apr-88	<a href="#">0.18</a>
Mustard Gas	cancer	LC	505-60-2	27-Feb-87	
MX (3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone)	cancer	<a href="#">SQE</a>	77439-76-0	22-Dec-00	<a href="#">0.11</a>
Myclobutanil	developmental, male	<a href="#">AB</a>	88671-89-0	16-Apr-99	
beta-Myrcene	cancer	<a href="#">AB</a>	123-35-3	27-Mar-15	
Nabam	developmental	<a href="#">AB</a>	142-59-6	30-Mar-99	
Nafarelin acetate	developmental	FR	86220-42-0	1-Apr-90	
Nafenopin	cancer	SQE	3771-19-5	1-Apr-88	
Nalidixic acid	cancer	<a href="#">AB</a>	389-08-2	15-May-98	<a href="#">28</a>

Naphthalene	cancer	<a href="#">AB</a>	91-20-3	19-Apr-02	<a href="#">5.8</a>
1-Naphthylamine	cancer	LC	134-32-7	1-Oct-89	
2-Naphthylamine	cancer	LC	91-59-8	27-Feb-87	<a href="#">0.4</a>
Neomycin sulfate (internal use)	developmental	FR	1405-10-3	1-Oct-92	
Netilmicin sulfate	developmental	FR	56391-57-2	1-Jul-90	
Nickel (Metallic)	cancer	LC	7440-02-0	1-Oct-89	
Nickel acetate	cancer	LC	373-02-4	1-Oct-89	
Nickel carbonate	cancer	LC	3333-67-3	1-Oct-89	
Nickel carbonyl	cancer	SQE	13463-39-3	1-Oct-87	
Nickel carbonyl	developmental	AB	13463-39-3	1-Sep-96	
Nickel compounds	cancer	<a href="#">LC</a>	---	7-May-04	
Nickel (soluble compounds)	developmental, male	<a href="#">SQE</a>	---	26-Oct-18	
Nickel hydroxide	cancer	LC	12054-48-7; 12125-56-3	1-Oct-89	
Nickelocene	cancer	LC	1271-28-9	1-Oct-89	
Nickel oxide	cancer	LC	1313-99-1	1-Oct-89	
Nickel refinery dust from the pyrometallurgical process	cancer	SQE	---	1-Oct-87	0.8
Nickel subsulfide	cancer	SQE	12035-72-2	1-Oct-87	0.4
Nicotine	developmental	FR	54-11-5	1-Apr-90	
Nifedipine	developmental, female, male	<a href="#">FR</a>	21829-25-4	29-Jan-99	
Nimodipine	developmental	<a href="#">FR</a>	66085-59-4	24-Apr-01	
Niridazole	cancer	SQE	61-57-4	1-Apr-88	
Nitrapyrin [ <a href="#">Basis for listing changed effective on November 4, 2015</a> ]	cancer	SQE	1929-82-4	5-Oct-05	
Nitrapyrin	developmental	<a href="#">AB</a>	1929-82-4	30-Mar-99	
Nitritotriacetic acid	cancer	SQE	139-13-9	1-Jan-88	<a href="#">100</a>
Nitritotriacetic acid, trisodium salt monohydrate	cancer	SQE	18662-53-8	1-Apr-89	<a href="#">70</a>
5-Nitroacenaphthene	cancer	SQE	602-87-9	1-Apr-88	<a href="#">6</a>
<a href="#">5-Nitro-o-anisidine Delisted December 8, 2006 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">LC</a>	<a href="#">99-59-2</a>	<a href="#">1-Oct-89</a>	<a href="#">10</a>
<i>o</i> -Nitroanisole	cancer	AB	91-23-6	1-Oct-92	
<i>para</i> -Nitroanisole	cancer	<a href="#">LC</a>	100-17-4	13-Sep-19	
Nitrobenzene	cancer	<a href="#">AB</a>	98-95-3	26-Aug-97	
Nitrobenzene	male	<a href="#">AB</a>	98-95-3	30-Mar-10	
4-Nitrobiphenyl	cancer	SQE	92-93-3	1-Apr-88	
6-Nitrochrysene	cancer	AB	2/8/7496	1-Oct-90	
Nitrofen (technical grade)	cancer	SQE	1836-75-5	1-Jan-88	<a href="#">9</a>
2-Nitrofluorene	cancer	AB	607-57-8	1-Oct-90	
Nitrofurantoin	male	AB	67-20-9	1-Apr-91	
Nitrofurazone	cancer	AB	59-87-0	1-Jan-90	<a href="#">0.5</a>

1-[(5-Nitrofurfurylidene)-amino]-2-imidazolidinone	cancer	SQE	555-84-0	1-Apr-88	<a href="#">0.4</a>
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide	cancer	SQE	531-82-8	1-Apr-88	<a href="#">0.5</a>
Nitrogen mustard (Mechlorethamine)	cancer	SQE	51-75-2	1-Jan-88	
Nitrogen mustard (Mechlorethamine)	developmental	SQE	51-75-2	1-Jan-89	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	cancer	SQE	55-86-7	1-Apr-88	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	FR	55-86-7	1-Jul-90	
Nitrogen mustard N-oxide	cancer	SQE	126-85-2	1-Apr-88	
Nitrogen mustard N-oxide hydrochloride	cancer	SQE	302-70-5	1-Apr-88	
Nitromethane	cancer	<a href="#">AB</a>	75-52-5	1-May-97	<a href="#">39</a>
2-Nitropropane	cancer	SQE	79-46-9	1-Jan-88	
1-Nitropyrene	cancer	<a href="#">AB</a>	5522-43-0	1-Oct-90	
4-Nitropyrene	cancer	<a href="#">AB</a>	57835-92-4	1-Oct-90	
N-Nitrosodi-n-butylamine	cancer	SQE	924-16-3	1-Oct-87	0.06
N-Nitrosodiethanolamine	cancer	SQE	1116-54-7	1-Jan-88	0.3
N-Nitrosodiethylamine	cancer	SQE	55-18-5	1-Oct-87	0.02
N-Nitrosodimethylamine	cancer	SQE	62-75-9	1-Oct-87	0.04
p-Nitrosodiphenylamine	cancer	SQE	156-10-5	1-Jan-88	<a href="#">30</a>
N-Nitrosodiphenylamine	cancer	SQE	86-30-6	1-Apr-88	80
N-Nitrosodi-n-propylamine	cancer	SQE	621-64-7	1-Jan-88	0.1
N-Nitroso-N-ethylurea	cancer	SQE	759-73-9	1-Oct-87	0.03
N-Nitrosohexamethyleneimine	cancer	SQE	932-83-2	23-Nov-18	
3-(N-Nitrosomethylamino) propionitrile	cancer	<a href="#">AB</a>	60153-49-3	1-Apr-90	
4-(N-Nitrosomethylamino)-1-(3-pyridyl)1-butanone	cancer	<a href="#">AB</a>	64091-91-4	1-Apr-90	<a href="#">0.014</a>
N-Nitrosomethyl-n-butylamine	cancer	<a href="#">SQE</a>	7068-83-9	26-Dec-14	
N-Nitrosomethyl-n-decylamine	cancer	<a href="#">SQE</a>	75881-22-0	26-Dec-14	
N-Nitrosomethyl-n-dodecylamine	cancer	<a href="#">SQE</a>	55090-44-3	26-Dec-14	
N-Nitrosomethylethylamine	cancer	<a href="#">LC</a>	10595-95-6	1-Oct-89	0.03
N-Nitrosomethyl-n-heptylamine	cancer	<a href="#">SQE</a>	16338-99-1	26-Dec-14	
N-Nitrosomethyl-n-hexylamine	cancer	<a href="#">SQE</a>	28538-70-7	26-Dec-14	
N-Nitrosomethyl-n-nonylamine	cancer	<a href="#">SQE</a>	75881-19-5	26-Dec-14	
N-Nitrosomethyl-n-octylamine	cancer	<a href="#">SQE</a>	34423-54-6	26-Dec-14	
N-Nitrosomethyl-n-pentylamine	cancer	<a href="#">SQE</a>	13256-07-0	26-Dec-14	
N-Nitrosomethyl-n-propylamine	cancer	<a href="#">SQE</a>	924-46-9	26-Dec-14	
N-Nitrosomethyl-n-tetradecylamine	cancer	<a href="#">SQE</a>	75881-20-8	26-Dec-14	
N-Nitrosomethyl-n-undecylamine	cancer	<a href="#">SQE</a>	68107-26-6	26-Dec-14	
N-Nitroso-N-methylurea	cancer	SQE	684-93-5	1-Oct-87	0.006
N-Nitroso-N-methylurethane	cancer	SQE	615-53-2	1-Apr-88	<a href="#">0.006</a>
N-Nitrosomethylvinylamine	cancer	SQE	4549-40-0	1-Jan-88	
N-Nitrosomorpholine	cancer	SQE	59-89-2	1-Jan-88	<a href="#">0.1</a>
N-Nitrosornicotine	cancer	SQE	16543-55-8	1-Jan-88	<a href="#">0.5</a>
N-Nitrosopiperidine	cancer	SQE	100-75-4	1-Jan-88	<a href="#">0.07</a>
N-Nitrosopyrrolidine	cancer	SQE	930-55-2	1-Oct-87	0.3
N-Nitrososarcosine	cancer	SQE	13256-22-9	1-Jan-88	

o-Nitrotoluene	cancer	<a href="#">AB</a>	88-72-2	15-May-98	
Nitrous oxide [ <a href="#">Basis for listing changed effective November 8, 2013</a> ]	developmental, female	<a href="#">AB</a>	10024-97-2	1-Aug-08	
Norethisterone (Norethindrone)	cancer	LC	68-22-4	1-Oct-89	
Norethisterone (Norethindrone)	developmental	FR	68-22-4	1-Apr-90	
Norethisterone acetate (Norethindrone acetate)	developmental	FR	51-98-9	1-Oct-91	
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	FR	68-22-4/ 57-63-6	1-Apr-90	
Norethisterone (Norethindrone) /Mestranol	developmental	FR	68-22-4/ 72-33-3	1-Apr-90	
Norethynodrel	cancer	<a href="#">AB</a>	68-23-5	27-Feb-01	
Norgestrel	developmental	FR	6533-00-2	1-Apr-90	
Ochratoxin A	cancer	AB	303-47-9	1-Jul-90	
Oil Orange SS	cancer	SQE	2646-17-5	1-Apr-88	
Oral contraceptives, combined	cancer	LC	---	1-Oct-89	
Oral contraceptives, sequential	cancer	LC	---	1-Oct-89	
Oryzalin	cancer	<a href="#">AB</a>	19044-88-3	12-Sep-08	
Oxadiazon	cancer	SQE	19666-30-9	1-Jul-91	
Oxadiazon	developmental	<a href="#">AB</a>	19666-30-9	15-May-98	
Oxazepam	cancer	AB	604-75-1	1-Oct-94	
Oxazepam	developmental	FR	604-75-1	1-Oct-92	
<a href="#">p,p'-Oxybis(benzenesulfonyl hydrazide)</a> <a href="#">Delisted December 13, 2013 [Click here for the basis for delisting]</a>	developmental	<a href="#">LC</a>	<a href="#">80-51-3</a>	<a href="#">7-Aug-09</a>	
Oxydemeton methyl	female, male	<a href="#">AB</a>	301-12-2	6-Nov-98	
Oxymetholone	cancer	SQE	434-07-1	1-Jan-88	
Oxymetholone	developmental	<a href="#">FR</a>	434-07-1	1-May-97	
Oxytetracycline (internal use)	developmental	FR	79-57-2	1-Jan-91	
Oxytetracycline hydrochloride (internal use)	developmental	FR	2058-46-0	1-Oct-91	
Oxythioquinox (Chinomethionat)	cancer	<a href="#">AB</a>	1/2/2439	20-Aug-99	
Oxythioquinox (Chinomethionat)	developmental	<a href="#">AB</a>	1/2/2439	6-Nov-98	
Paclitaxel	developmental, female, male	<a href="#">FR</a>	33069-62-4	26-Aug-97	
Palygorskite fibers (> 5µm in length)	cancer	<a href="#">AB</a>	12174-11-7	28-Dec-99	
Panfuran S	cancer	SQE	794-93-4	1-Jan-88	
Paramethadione	developmental	FR	115-67-3	1-Jul-90	
Parathion	cancer	<a href="#">LC</a>	56-38-2	20-May-16	
Penicillamine	developmental	FR	52-67-5	1-Jan-91	

pentabromodiphenyl ether mixture [DE-71 (technical grade)]	cancer	<a href="#">AB</a>	---	7-Jul-17	
Pentachlorophenol	cancer	<a href="#">AB</a>	87-86-5	1-Jan-90	40
Pentachlorophenol and by-products of its synthesis (complex mixture)	cancer	<a href="#">AB</a>	---	21-Oct-16	
Pentobarbital sodium	developmental	<a href="#">FR</a>	57-33-0	1-Jul-90	
Pentosan polysulfate sodium	cancer	<a href="#">LC</a>	---	18-Apr-14	
Pentostatin	developmental	<a href="#">FR</a>	53910-25-1	1-Sep-96	
Perfluorononanoic acid (PFNA) and its salts	male	<a href="#">SQE</a>	---	31-Dec-21	
Perfluorooctane sulfonate (PFOS)	developmental	<a href="#">AB</a>	1763-23-1	10-Nov-17	
Perfluorooctane sulfonic acid (PFOS) and its salts and transformation and degradation precursors	cancer	<a href="#">SQE</a>	---	24-Dec-21	
Perfluorooctanoic acid (PFOA)	cancer	<a href="#">AB</a>	335-67-1	25-Feb-22	
Perfluorooctanoic acid (PFOA)	developmental	<a href="#">AB</a>	335-67-1	10-Nov-17	
Pertuzumab	developmental	<a href="#">FR</a>	380610-27-5	27-Jan-17	
Phenacetamide	developmental	<a href="#">FR</a>	63-98-9	1-Jul-90	
Phenacetin	cancer	<a href="#">LC</a>	62-44-2	1-Oct-89	<a href="#">300</a>
Phenazopyridine	cancer	<a href="#">SQE</a>	94-78-0	1-Jan-88	<a href="#">4</a>
Phenazopyridine hydrochloride	cancer	<a href="#">SQE</a>	136-40-3	1-Jan-88	<a href="#">5</a>
Phenesterin	cancer	<a href="#">SQE</a>	10/9/3546	1-Jul-89	<a href="#">0.005</a>
Phenobarbital	cancer	<a href="#">AB</a>	50-06-6	1-Jan-90	<a href="#">2</a>
Phenolphthalein	cancer	<a href="#">AB</a>	77-09-8	15-May-98	
Phenoxybenzamine	cancer	<a href="#">SQE</a>	59-96-1	1-Apr-88	<a href="#">0.2</a>
Phenoxybenzamine hydrochloride	cancer	<a href="#">SQE</a>	63-92-3	1-Apr-88	<a href="#">0.3</a>
Phenprocoumon	developmental	<a href="#">FR</a>	435-97-2	1-Oct-92	
<i>o</i> -Phenylenediamine and its salts	cancer	<a href="#">AB</a>	95-54-5	15-May-98	
<i>o</i> -Phenylenediamine					<a href="#">26</a>
<i>o</i> -Phenylenediamine dihydrochloride					<a href="#">44</a>
Phenyl glycidyl ether	cancer	<a href="#">AB</a>	122-60-1	1-Oct-90	<a href="#">5</a>
<a href="#">Phenyl glycidyl ether</a> <a href="#">Delisted April 4, 2014 [Click here for the basis for delisting]</a>	<del>male</del>	<a href="#">LC</a>	<del>122-60-1</del>	<del>7-Aug-09</del>	
Phenylhydrazine and its salts	cancer	<a href="#">AB</a>	---	1-Jul-92	
Phenylhydrazine					<a href="#">1</a>
Phenylhydrazine hydrochloride					<a href="#">1.4</a>
<i>o</i> -Phenylphenate, sodium	cancer	<a href="#">AB</a>	132-27-4	1-Jan-90	<a href="#">200</a>
<i>o</i> -Phenylphenol	cancer	<a href="#">AB</a>	90-43-7	4-Aug-00	
Phenylphosphine [ <a href="#">Basis for listing changed effective June 6, 2014</a> ]	developmental male	<a href="#">LC SQE</a>	638-21-1	7-Aug-09	
PhiP(2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine)	cancer	<a href="#">AB</a>	105650-23-5	1-Oct-94	

Pimozide	developmental, female	<a href="#">FR</a>	2062-78-4	20-Aug-99	
Pioglitazone	cancer	<a href="#">LC</a>	111025-46-8	18-Apr-14	
Pipobroman	developmental	FR	54-91-1	1-Jul-90	
Pirimicarb	cancer	<a href="#">AB</a>	23103-98-2	1-Jul-08	
Plicamycin	developmental	FR	18378-89-7	1-Apr-90	
Polybrominated biphenyls	cancer	SQE	---	1-Jan-88	0.02
Polybrominated biphenyls	developmental	AB	---	1-Oct-94	
Polychlorinated biphenyls	cancer	LC	---	1-Oct-89	0.09
Polychlorinated biphenyls	developmental	SQE	---	1-Jan-91	
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	cancer	SQE	---	1-Jan-88	
Polychlorinated dibenzo- <i>p</i> -dioxins	cancer	FR	---	1-Oct-92	
Polychlorinated dibenzofurans	cancer	FR	---	1-Oct-92	
Polygeenan	cancer	SQE	53973-98-1	1-Jan-88	<a href="#">1200</a>
Ponceau MX	cancer	SQE	3761-53-3	1-Apr-88	<a href="#">200</a>
Ponceau 3R	cancer	SQE	9/8/3564	1-Apr-88	<a href="#">40</a>
Potassium bromate	cancer	AB	1/2/7758	1-Jan-90	<a href="#">1</a>
Potassium dimethyldithiocarbamate	developmental	<a href="#">AB</a>	128-03-0	30-Mar-99	<a href="#">720</a>
Pravastatin sodium	developmental	<a href="#">FR</a>	81131-70-6	3-Mar-00	
Prednisolone sodium phosphate	developmental	<a href="#">FR</a>	125-02-0	20-Aug-99	
Primidone	cancer	<a href="#">AB</a>	125-33-7	20-Aug-99	
Procarbazine	cancer	SQE	671-16-9	1-Jan-88	<a href="#">0.05</a>
Procarbazine hydrochloride	cancer	SQE	366-70-1	1-Jan-88	<a href="#">0.06</a>
Procarbazine hydrochloride	developmental	FR	366-70-1	1-Jul-90	
Procymidone	cancer	AB	32809-16-8	1-Oct-94	
Progesterone	cancer	SQE	57-83-0	1-Jan-88	
Pronamide	cancer	AB	23950-58-5	1-May-96	
Propachlor	cancer	<a href="#">AB</a>	1918-16-7	27-Feb-01	
1,3-Propane sultone	cancer	SQE	1120-71-4	1-Jan-88	<a href="#">0.3</a>
Propargite	cancer	AB	2312-35-8	1-Oct-94	
Propargite	developmental	<a href="#">AB</a>	2312-35-8	15-Jun-99	
Propazine	developmental, female	<a href="#">AB</a>	139-40-2	15-Jul-16	<a href="#">100 (oral)</a>
beta-Propiolactone	cancer	SQE	57-57-8	1-Jan-88	<a href="#">0.05</a>
Propoxur	cancer	<a href="#">AB</a>	114-26-1	11-Aug-06	
Propylene glycol mono- <i>t</i> -butyl ether	cancer	<a href="#">AB</a>	57018-52-7	11-Jun-04	
Propylene oxide	cancer	SQE	75-56-9	1-Oct-88	
Propylthiouracil	cancer	SQE	51-52-5	1-Jan-88	<a href="#">0.7</a>
Propylthiouracil	developmental	FR	51-52-5	1-Jul-90	

Pulegone	cancer	<a href="#">LC</a>	89-82-7	18-Apr-14	
Pymetrozine	cancer	<a href="#">AB</a>	123312-89-0	22-Mar-11	
Pyridine	cancer	<a href="#">AB</a>	110-86-1	17-May-02	
Pyrimethamine	developmental	<a href="#">FR</a>	58-14-0	29-Jan-99	
Quazepam	developmental	<a href="#">FR</a>	36735-22-5	26-Aug-97	
Quinoline and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Quizalofop-ethyl	male	<a href="#">SQE</a>	76578-14-8	24-Dec-99	<a href="#">590</a>
Radionuclides	cancer	SQE	---	1-Jul-89	
Reserpine	cancer	LC	50-55-5	1-Oct-89	<a href="#">0.06</a>
Residual (heavy) fuel oils	cancer	AB	---	1-Oct-90	
Resmethrin	cancer	<a href="#">AB</a>	10453-86-8	1-Jul-08	
Resmethrin	developmental	<a href="#">AB</a>	10453-86-8	6-Nov-98	
Retinoid/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)	developmental	SQE	---	1-Jul-89	
Ribavirin	developmental	FR	36791-04-5	1-Apr-90	
Ribavirin	male	<a href="#">FR</a>	36791-04-5	27-Feb-01	
Riddelliine	cancer	<a href="#">LC</a>	23246-96-0	3-Dec-04	
Rifampin	developmental, female	<a href="#">FR</a>	13292-46-1	27-Feb-01	
<a href="#">Saccharin Delisted April 6, 2001 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">LC</a>	<a href="#">81-07-2</a>	<a href="#">1-Oct-89</a>	
<a href="#">Saccharin, sodium Delisted January 17, 2003 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">SQE</a>	<a href="#">128-44-9</a>	<a href="#">1-Jan-88</a>	
Safrole	cancer	SQE	94-59-7	1-Jan-88	<a href="#">3</a>
Salted fish, Chinese-style	cancer	<a href="#">LC</a>	---	29-Apr-11	
Secobarbital sodium	developmental	FR	309-43-3	1-Oct-92	
Sedaxane	cancer	<a href="#">AB</a>	874967-67-6	1-Jul-16	
Selenium sulfide	cancer	LC	7446-34-6	1-Oct-89	
Sermorelin acetate	developmental	<a href="#">FR</a>	---	20-Aug-99	
Shale-oils	cancer	AB	68308-34-9	1-Apr-90	
Silica, crystalline (airborne particles of respirable size)	cancer	SQE	---	1-Oct-88	
Silicon carbide whiskers	cancer	LC	---	17-Nov-23	
Simazine	developmental, female	<a href="#">AB</a>	122-34-9	15-Jul-16	<a href="#">100 (oral)</a>

					<a href="#">23 (oral)</a>
Sodium dimethyldithiocarbamate	developmental	<a href="#">AB</a>	128-04-1	30-Mar-99	<a href="#">58 (oral) as a 40% pesticidal formulation</a>
Sodium fluoroacetate	male	<a href="#">AB</a>	62-74-8	6-Nov-98	
Soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils)	cancer	LC	---	27-Feb-87	
Spirodiclofen	cancer	<a href="#">AB</a>	148477-71-8	8-Oct-10	
Spironolactone	cancer	<a href="#">FR</a>	52-01-7	1-May-97	
Stanozolol	cancer	<a href="#">FR</a>	10418-03-8	1-May-97	
Sterigmatocystin	cancer	SQE	10048-13-2	1-Apr-88	<a href="#">0.02</a>
Streptomycin sulfate	developmental	FR	3810-74-0	1-Jan-91	
Streptozocin (streptozotocin)	developmental, female, male	<a href="#">FR</a>	18883-66-4	20-Aug-99	
Streptozotocin (streptozocin)	cancer	SQE	18883-66-4	1-Jan-88	<a href="#">0.006</a>
Strong inorganic acid mists containing sulfuric acid	cancer	<a href="#">AB</a>	---	14-Mar-03	
Styrene	cancer	<a href="#">AB</a>	100-42-5	22-Apr-16	<a href="#">27</a>
Styrene oxide	cancer	SQE	96-09-3	1-Oct-88	<a href="#">4</a>
Sulfallate	cancer	SQE	95-06-7	1-Jan-88	<a href="#">4</a>
Sulfasalazine (Salicylazosulfapyridine)	cancer	<a href="#">AB</a>	599-79-1	15-May-98	
Sulfasalazine (Salicylazosulfapyridine)	male	<a href="#">FR</a>	599-79-1	29-Jan-99	
Sulfur dioxide <sup>e</sup>	developmental	<a href="#">SQE</a>	9/5/7446	29-Jul-11	<a href="#">10000</a>
Sulindac	developmental, female	<a href="#">FR</a>	38194-50-2	29-Jan-99	
Talc containing asbestiform fibers	cancer	AB	---	1-Apr-90	
Tamoxifen and its salts	cancer	SQE	10540-29-1	1-Sep-96	
Tamoxifen citrate	developmental	FR	54965-24-1	1-Jul-90	
Temazepam	developmental	FR	846-50-4	1-Apr-90	
Teniposide	developmental	FR	29767-20-2	1-Sep-96	
Terbacil	developmental	<a href="#">AB</a>	5902-51-2	18-May-99	
Teriparatide	cancer	FR	52232-67-4	14-Aug-15	
Terrazole	cancer	AB	2593-15-9	1-Oct-94	
Testosterone and its esters	cancer	SQE	58-22-0	1-Apr-88	
Testosterone cypionate	developmental	FR	58-20-8	1-Oct-91	
Testosterone enanthate	developmental	FR	315-37-7	1-Apr-90	
Tetrabromobisphenol A	cancer	<a href="#">LC</a>	79-94-7	27-Oct-17	
3,3',4,4'-Tetrachloroazobenzene	cancer	<a href="#">AB</a>	14047-09-7	24-Jul-12	
2,3,7,8-Tetrachlorodibenzo-p- dioxin (TCDD)	cancer	SQE	1746-01-6	1-Jan-88	0.000005

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	developmental	AB	1746-01-6	1-Apr-91	
1,1,1,2-Tetrachloroethane	cancer	<a href="#">LC</a>	630-20-6	13-Sep-13	
1,1,2,2-Tetrachloroethane	cancer	AB	79-34-5	1-Jul-90	<a href="#">3</a>
Tetrachloroethylene (Perchloroethylene)	cancer	SQE	127-18-4	1-Apr-88	14
<i>p-a,a,a</i> -Tetrachlorotoluene	cancer	AB	5216-25-1	1-Jan-90	
Tetrachlorvinphos	cancer	<a href="#">LC</a>	22248-79-9	20-May-16	
Tetracycline (internal use)	developmental	FR	60-54-8	1-Oct-91	
Tetracyclines (internal use)	developmental	FR	---	1-Oct-92	
Tetracycline hydrochloride (internal use)	developmental	FR	64-75-5	1-Jan-91	
Tetrafluoroethylene	cancer	<a href="#">AB</a>	116-14-3	1-May-97	
$\Delta^9$ -Tetrahydrocannabinol ( $\Delta^9$ -THC)	developmental	<a href="#">SQE</a>		3-Jan-20	
Tetrahydrofuran	cancer	<a href="#">LC</a>	109-99-9	17-Dec-21	
Tetranitromethane	cancer	AB	509-14-8	1-Jul-90	<a href="#">0.059</a>
Thalidomide	developmental	SQE	50-35-1	1-Jul-87	
Thioacetamide	cancer	SQE	62-55-5	1-Jan-88	<a href="#">0.1</a>
4,4'-Thiodianiline	cancer	SQE	139-65-1	1-Apr-88	<a href="#">0.05</a>
Thiodicarb	cancer	<a href="#">AB</a>	59669-26-0	20-Aug-99	
Thioguanine	developmental	FR	154-42-7	1-Jul-90	
Thiophanate methyl	female, male	<a href="#">AB</a>	23564-05-8	18-May-99	<a href="#">600 (oral)</a>
Thiouracil	cancer	---	141-90-2	11-Jun-04	
Thiourea	cancer	SQE	62-56-6	1-Jan-88	<a href="#">10</a>
Thorium dioxide	cancer	LC	1314-20-1	27-Feb-87	
Titanium dioxide (airborne, unbound particles of respirable size)	cancer	<a href="#">LC</a>	---	2-Sep-11	
Tobacco, oral use of smokeless products	cancer	SQE	---	1-Apr-88	
Tobacco smoke	cancer	SQE	---	1-Apr-88	
Tobacco smoke (primary)	developmental, female, male	SQE	---	1-Apr-88	
Tobramycin sulfate	developmental	FR	49842-07-1	1-Jul-90	
Toluene	developmental	SQE	108-88-3	1-Jan-91	7000 <sup>c</sup>
<a href="#">Toluene [Click here for the basis for the removal of female reproductive endpoint effective March 7, 2014]</a>	<del>female</del>	<a href="#">LC</a>	<del>108-88-3</del>	<del>7-Aug-09</del>	
Toluene diisocyanate	cancer	LC	26471-62-5	1-Oct-89	<a href="#">20</a>
<i>o</i> -Toluidine	cancer	SQE	95-53-4	1-Jan-88	<a href="#">4</a>
<i>o</i> -Toluidine hydrochloride	cancer	SQE	636-21-5	1-Jan-88	<a href="#">5</a>
<a href="#">para-Toluidine Delisted October 29, 1999 [Click here for the basis for delisting]</a>	<del>cancer</del>	<del>AB</del>	<del>106-49-0</del>	<del>1-Jan-90</del>	
Topiramate	developmental	<a href="#">FR</a>	97240-79-4	27-Nov-15	

Toxaphene (Polychlorinated camphenes)	cancer	SQE	8001-35-2	1-Jan-88	0.6
Toxins derived from <i>Fusarium moniliforme</i> ( <i>Fusarium verticillioides</i> )	cancer	<a href="#">LC</a>	---	7-Aug-09	
Treosulfan	cancer	LC	299-75-2	27-Feb-87	
Triadimefon	developmental, female, male	<a href="#">AB</a>	43121-43-3	30-Mar-99	
Triamterene	cancer	<a href="#">LC</a>	396-01-0	18-Apr-14	
Triazolam	developmental	FR	28911-01-5	1-Apr-90	
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF)	cancer	<a href="#">AB</a>	78-48-8	25-Feb-11	
Tributyltin methacrylate	developmental	<a href="#">AB</a>	2155-70-6	1-Dec-99	
Trichlormethine (Trimustine hydrochloride)	cancer	AB	817-09-4	1-Jan-92	
Trichloroacetic acid	cancer	<a href="#">LC</a>	76-03-9	13-Sep-13	<a href="#">9.9</a>
1,1,1-Trichloroethane	cancer	<a href="#">LC</a>	71-55-6	21-Apr-23	
Trichloroethylene	cancer	SQE	79-01-6	1-Apr-88	<a href="#">14 (oral)</a> <a href="#">50 (inhalation)</a>
Trichloroethylene	developmental, male	<a href="#">AB</a>	79-01-6	31-Jan-14	
2,4,6-Trichlorophenol	cancer	SQE	88-06-2	1-Jan-88	10
1,2,3-Trichloropropane	cancer	AB	96-18-4	1-Oct-92	
Trientine hydrochloride	developmental	<a href="#">FR</a>	38260-01-4	27-Feb-01	
Triforine	developmental	<a href="#">AB</a>	26644-46-2	18-Jun-99	
<a href="#">1,3,5-Triglycidyl-s-triazinetriene Delisted December 13, 2013 [Click here for the basis for delisting]</a>	male-	<a href="#">LC</a>	<a href="#">2451-62-9</a>	<a href="#">7-Aug-09</a>	
Trilostane	developmental	FR	13647-35-3	1-Apr-90	
Trimethadione	developmental	FR	127-48-0	1-Jan-91	
2,4,5-Trimethylaniline and its strong acid salts	cancer	<a href="#">SQE</a>	---	24-Oct-97	
Trimethylolpropane triacrylate, tech	cancer	<a href="#">LC</a>	---	17-Dec-21	
Trimethyl phosphate	cancer	AB	512-56-1	1-May-96	<a href="#">24</a>
Trimetrexate glucuronate	developmental	<a href="#">FR</a>	82952-64-5	26-Aug-97	
TRIM® VX	cancer	<a href="#">AB</a>	---	25-May-18	
2,4,6-Trinitrotoluene (TNT)	cancer	<a href="#">SQE</a>	118-96-7	19-Dec-08	<a href="#">8.2</a>
Triphenyltin hydroxide	cancer	AB	76-87-9	1-Jul-92	
Triphenyltin hydroxide	developmental	<a href="#">AB</a>	76-87-9	18-Mar-02	
<a href="#">Tris(aziridinyl)-p-benzoquinone (Triaziquone) Delisted December 8, 2006 [Click here for the basis for delisting]</a>	cancer	<a href="#">LC</a>	<a href="#">68-76-8</a>	<a href="#">1-Oct-89</a>	

Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	cancer	SQE	52-24-4	1-Jan-88	<a href="#">0.06</a>
Tris(2-chloroethyl) phosphate	cancer	AB	115-96-8	1-Apr-92	
Tris(2,3-dibromopropyl)phosphate	cancer	SQE	126-72-7	1-Jan-88	<a href="#">0.3</a>
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	cancer	<a href="#">SQE</a>	13674-87-8	28-Oct-11	<a href="#">5.4</a>
Trp-P-1 (Tryptophan-P-1)	cancer	SQE	62450-06-0	1-Apr-88	<a href="#">0.03</a>
Trp-P-2 (Tryptophan-P-2)	cancer	SQE	62450-07-1	1-Apr-88	<a href="#">0.2</a>
Trypan blue (commercial grade)	cancer	LC	72-57-1	1-Oct-89	
Unleaded gasoline (wholly vaporized)	cancer	SQE	---	1-Apr-88	
Uracil mustard	cancer	SQE	66-75-1	1-Apr-88	
Uracil mustard	developmental, female, male	FR	66-75-1	1-Jan-92	
Urethane (Ethyl carbamate)	cancer	SQE	51-79-6	1-Jan-88	0.7
Urethane (Ethyl carbamate)	developmental	AB	51-79-6	1-Oct-94	
Urofollitropin	developmental	FR	97048-13-0	1-Apr-90	
Valproate (Valproic acid)	developmental	SQE	99-66-1	1-Jul-87	
Vanadium pentoxide (orthorhombic crystalline form)	cancer	<a href="#">AB</a>	1314-62-1	11-Feb-05	
Vinblastine sulfate	developmental	FR	143-67-9	1-Jul-90	
Vinclozolin [basis for listing changed on November 16, 2006]	cancer	SQE	50471-44-8	20-Aug-99	
Vinclozolin	developmental	<a href="#">AB</a>	50471-44-8	15-May-98	
Vincristine sulfate	developmental	FR	2068-78-2	1-Jul-90	
Vinyl bromide	cancer	SQE	593-60-2	1-Oct-88	
Vinyl chloride	cancer	LC	75-01-4	27-Feb-87	3
4-Vinylcyclohexene	cancer	AB	100-40-3	1-May-96	
4-Vinylcyclohexene [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female, <del>male</del>	<a href="#">SQE</a>	100-40-3	7-Aug-09	
4-Vinyl-1-cyclohexene diepoxide (Vinyl cyclohexenedioxide)	cancer	AB	106-87-6	1-Jul-90	
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide) [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female, <del>male</del>	<a href="#">SQE</a>	106-87-6	1-Aug-08	
Vinyl fluoride	cancer	<a href="#">AB</a>	75-02-5	1-May-97	
Vinylidene chloride (1,1-Dichloroethylene)	cancer	<a href="#">LC</a>	75-35-4	29-Dec-17	<a href="#">0.88</a>
Vinyl trichloride (1,1,2-Trichloroethane)	cancer	AB	79-00-5	1-Oct-90	<a href="#">10</a>

Vismodegib	developmental, female, male	FR	879085-55-9	27-Jan-17	
Warfarin	developmental	SQE	81-81-2	1-Jul-87	
Wood dust	cancer	<a href="#">LC</a>	---	18-Dec-09	
2,6-Xylidine (2,6-Dimethylaniline)	cancer	AB	87-62-7	1-Jan-91	<a href="#">110</a>
Zalcitabine	cancer	<a href="#">LC</a>	7481-89-2	7-Aug-09	
Zidovudine (AZT)	cancer	<a href="#">LC</a>	30516-87-1	18-Dec-09	
Zileuton	cancer, developmental, female	<a href="#">FR</a>	111406-87-2	22-Dec-00	
<a href="#">Zineb Delisted October 29, 1999 [Click here for the basis for delisting]</a>	<a href="#">cancer</a>	<a href="#">AB</a>	<del>12122-67-7</del>	<del>1-Jan-90</del>	
<p>where a source or product results in exposures by multiple routes, the total exposure must be considered. For example, the MADL for benzene is exceeded when the absorbed dose exceeds 24 µg/day. If only inhalation and oral exposure occurs, the benzene MADL is exceeded when: (oral dose ÷ 24 µg/day) + (inhalation dose ÷ 49 µg/day) &gt; 1.0.</p>					
<p><sup>o</sup> Levels for male children and adolescents were calculated by application of the default bodyweights specified in Section 25703(a)(8) to the procedure specified in Sections 25801 and 25803</p>					
<p>Level represents absorbed dose (rounded from 6,525 µg/day). Since 100% of ingested toluene is absorbed, oral dose is equivalent to administered dose. It is assumed that roughly 50% of the dose administered by the inhalation route is absorbed. Therefore the MADL for inhaled toluene is 13,000 µg/day (rounded from 13,050 µg/day), corresponding to an absorbed dose of 6,525 µg/day.</p>					

d Butyl benzyl phthalate MADL was adopted June 25, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.					
e Sulfur dioxide MADL was adopted July 11, 2013, but pursuant to Government Code section 11343.4 it becomes effective October 1, 2013.					
f Hydrogen cyanide and cyanide salts MADLs were adopted on August 7, 2013, but pursuant to Government Code section 11343.4 they become effective October 1, 2013.					

Last Updated 4/3/2025 Scott Sokoli

Signature: Scott Sokoli

Name: Scott Sokoli

Title: Compliance Manager Date: 4 / 3 / 2025

































































